The effect of vaccination on transmission of SARS-CoV-2 (COVID-19): a rapid review

Authors: Jessica Williams¹, Sasha Barratte¹, Tom Winfield¹, Lauren Elston¹, Katie McDermott¹, David Jarrom¹, Elise Hasler¹, Caron Potter¹, Ruth Lewis², Alison Cooper², Adrian Edwards²

1 Health Technology Wales, Wales, United Kingdom

2 Wales COVID-19 Evidence Centre, Wales, United Kingdom

Abstract:

This is an update (literature search up to 15 March 2022) of a rapid review examining whether vaccination against SARS-CoV-2 (COVID-19) affects transmission of SARS-CoV-2.

Streamlined systematic methodologies were used to accelerate the review process.

The update identified 17 additional studies: 6 studies reported on transmission and 11 studies reported viral load. There was high heterogeneity across studies, which varied in design, participant characteristics and SARS-CoV-2 variants reported. Evidence from this update supports previous findings that that transmission of Omicron and Delta variants is lowest in booster-vaccinated people, followed by fully vaccinated people, with the highest rate of transmission in unvaccinated people. Additionally, some studies compared transmission between different variants or subvariants; risk of transmission appears to be higher with Omicron than Delta, regardless of vaccination status.

Funding statement: Health Technology Wales was funded for this work by the Wales COVID-19 Evidence Centre, itself funded by Health and Care Research Wales on behalf of Welsh Government.

medRxiv preprint doi: https://doi.org/10.1101/2022.12.09.22283255; this version posted December 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-ND 4.0 International license .











Wales COVID-19 Evidence Centre (WCEC) **Rapid Review**

The effect of vaccination on transmission of SARS-CoV-2 (COVID-19): a rapid review

Update 02: Search to 15 March 2022

Report number – RR00054 (March 2022)

Rapid Review Details

Review conducted by: Health Technology Wales

Review Team: Jessica Williams, Sasha Barrate, Lauren Elston, Katie McDermott, Tom Winfield, David Jarrom, Elise Hasler, Carron Potter

Review submitted to the WCEC: March 2022

Rapid Review report issued by the WCEC: November 2022

WCEC Team:

Adrian Edwards, Alison Cooper, Ruth Lewis, Micaela Gal, Rebecca-Jane Law, Jane Greenwell and Ffion Coomber involved in drafting the Topline Summary, review and editing.

This review should be cited as:

RR00054. Wales COVID-19 Evidence Centre. A rapid review of the effect vaccination on Sars-CoV-2 (COVID-19) transmission. March 2022 update.

Disclaimer: The views expressed in this publication are those of the authors, not necessarily Health and Care Research Wales. The WCEC and authors of this work declare that they have no conflict of interest.

The effect of vaccination on transmission of SARS-CoV-2 (COVID-19): a rapid review

Update 02: Search to 15 March 2022 Report number – RR00054 (March 2022)

FULL REPORT

TOPLINE SUMMARY

What is a Rapid Review?

Our rapid reviews use a variation of the systematic review approach, abbreviating or omitting some components to generate the evidence to inform stakeholders promptly whilst maintaining attention to bias. They follow the methodological recommendations and minimum standards for conducting and reporting rapid reviews, including a structured protocol, systematic search, screening, data extraction, critical appraisal, and evidence synthesis to answer a specific question and identify key research gaps. They take 1-2 months, depending on the breadth and complexity of the research topic/ question(s), extent of the evidence base, and type of analysis required for synthesis.

This review is closely linked to a prior Rapid Review (RR) conducted by Wales COVID-19 Evidence Centre (WCEC) and published as: What is the risk of SARS-CoV-2 transmission in vaccinated populations? Report number - RR00012 (November 2021)

Background / Aim of Rapid Review

The COVID-19 vaccination programme has been successful in reducing the impact of severe COVID-19 disease on hospitalisation, morbidity and mortality. However, the effectiveness of COVID-19 vaccines against transmission is less clear, in particular for people with milder or asymptomatic infection, or in an era of new variants. We previously conducted a RR that aimed to examine evidence on the transmission risk of SARS-CoV-2 from vaccinated people to unvaccinated or vaccinated people (Report number - RR00012, November 2021). At the time of this previous review, the UK Health Security Agency (UKHSA) were setting up a living rapid review on the effect of COVID-19 vaccination on transmission of SARS-CoV-2. This Living RR was continued until January 2022 when the last update search was conducted (UKHSA, 2022). This RR represents an update (search up to 15 March 2022) of the last version of the UKHSA living RR, and addresses the following review questions:

- Does vaccination against COVID-19 affect transmission of SARS-CoV-2 to others, in the subgroup of people who contract COVID-19 post-vaccination?
- How does risk of onward transmission vary with vaccine type, completion of the vaccination course, duration after vaccination, at different baseline community transmission levels and SARS-CoV-2 variant in the vaccinated person?

Key Findings

Extent of the evidence base

The update identified 17 additional studies: 6 studies reported on transmission and 11 studies reported viral load. One additional ongoing RCT was also identified (estimated publication date December 2024.)

Recency of the evidence base

medRxiv preprint doi: https://doi.org/10.1101/2022.12.09.22283255; this version posted December 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

The update review included evidence published between 12 January 2022 (end date of last search) and 15 March 2022.

Main findings

- The main conclusions from the previous review were not changed from the inclusion of • 17 additional studies in this update.
- Fully and booster-vaccinated cases (infected persons) transmit SARS-CoV-2 less than unvaccinated cases, particularly for pre-Delta and Wild-type variants. This difference diminishes with time since vaccine dose, particularly for the Delta and Omicron variants.
- Studies of viral load showed similar findings, with most pre-Delta studies showing fully vaccinated cases had larger Ct values or lower viral loads than unvaccinated cases, but most Delta and Omicron studies showed no clear difference in Ct values between fully vaccinated and unvaccinated cases.
- The risk of transmission of the Omicron variant was found to be higher compared with the Delta variant, regardless of vaccination status.
- There was insufficient evidence to examine whether transmission varies by vaccine type or at different baseline community transmission levels.

Best quality evidence

Two studies reporting on transmission were considered high quality (Andrejko et al. 2021, Lyngse et al. 2022a), and three studies of viral load were judged to be high quality (Lyngse et al. 2022a, Migueres et al. 2022, Qassim et al. 2022).

Policy Implications

- The findings indicate that transmission of Omicron and Delta variants is lowest in booster-vaccinated people, followed by fully vaccinated people, with the highest rate of transmission in unvaccinated people.
- Where studies have compared transmission between different variants or sub-variants, the risk of transmission appears to be higher with Omicron than Delta, regardless of vaccination status.
- Most studies were highly heterogeneous, so caution must be used when comparing results.
- Randomised controlled trials of vaccination assessing transmission to household members or other close contacts would help to understand the true vaccine effectiveness against transmission of SARS-CoV-2. However, these would need to account for the ongoing development of new variants, which may be challenging.

Strength of Evidence

The new evidence consists of observational studies that are mainly good to moderate quality. However, in almost all studies there is a high risk that factors other than vaccination may have affected the findings and biased the results in either direction. The studies also varied in design, participant characteristics and SARS-CoV-2 variants reported.

Contents

1. New evidence on transmission of SARS-CoV-2 after COVID-19 vacc	ination6
2. New evidence on viral load in those who develop COVID-19 infect	ion after being
vaccinated	10
3. Inequalities	15
4. Limitations	15
5. Conclusion	16
6. Research needed	17
7. Acknowledgments	17
8. Summary Tables	17
9. References	50
10. Annex A: Methods	58
11. About the Wales COVID-19 Evidence Centre	64

1. New evidence on transmission of SARS-CoV-2 after COVID-19 vaccination (Table 1)

In this update, there were 6 observational studies that directly assessed the effectiveness of vaccines in reducing the risk of transmission of SARS-CoV-2 from people who had COVID-19 (index cases) to household members or close contacts (secondary cases). Four of the studies were pre-prints: Allen et al. (2022a), Jalali et al. (2022), Lyngse et al. (2022a), Sriraman et al. (2022). The six studies were appraised using the Quality Criteria Checklist (QCC) tool. Two studies were assessed as high quality (Andrejko et al. 2021, Lyngse et al. 2022a), three were of medium quality (Allen et al. 2022a, Jalali et al. 2022, Sriraman et al. 2022) and one study was of low quality (Brandal et al. 2021). Five were cohort studies (Allen et al. 2022a, Brandal et al. 2021, Jalali et al. 2022, Lyngse et al. 2022a, Sriraman et al. 2022) and one was a case-control study (Andrejko et al. 2021) One study provided data from the UK (Allen et al. 2022a), three from Europe (Brandal et al. 2021, Jalali et al. 2022, Lyngse et al. 2022a), one from Asia (Sriraman et al. 2022) and one from USA (Andrejko et al. 2021). The dates of studies being conducted ranged between January 2020 and 23 January 2022.

Two studies focussed on the Omicron variant (Brandal et al. 2021, Lyngse et al. 2022a), one study looked at the Delta variant (Sriraman et al. 2022), two studies looked at both variants (Allen et al. 2022a, Jalali et al. 2022), and one study did not report the variant, but was likely it looked at Delta as the study dates went from February 2021 to November 2021 (Andrejko et al. 2021).

The studies included people who had received COVID-19 booster vaccinations (three doses), those who were fully vaccinated (two doses), those who were partially vaccinated (one dose), and those who were unvaccinated (no vaccine doses).

Table 1 shows a summary of all transmission studies, including studies from both this update (with black text) and from the previous review (in grey text), and <u>Supplementary</u> Table 1 shows full information for all transmission studies.

1.1 Evidence for the Omicron variant

1.1.1 Transmission and vaccine effectiveness

There was one study from the previous review for transmission of Omicron variant SARS-CoV-2 (Lyngse et al. 2021). This study suggests that booster-vaccinated index cases transmit Omicron and Delta variant SARS-CoV-2 less than fully-vaccinated index cases, and that fully-vaccinated cases transmit less than unvaccinated index cases. There was little evidence that this was different for index cases with Omicron compared with Delta variant SARS-CoV-2. This study also suggested that there was little difference in Omicron variant SARS-CoV-2 transmission to fully vaccinated and unvaccinated household contacts, although there was less transmission to booster-vaccinated household contacts.

In addition to the study reported above, 3 studies included in this update (1 study just focused on Omicron and 2 studies looking at Omicron and Delta) looked at the difference in transmission of the Omicron variant from vaccinated and unvaccinated index cases. One

study included in this update looked at the effectiveness of vaccines in reducing Omicron SARS-CoV-2 transmission. These are described in more detail below.

Transmission

Lyngse et al. (2022a) expanded on the study above by Lyngse et al. (2021) and assessed the transmission of two subvariants of Omicron (BA.1 and BA.2) to household members in 8,541 primary household cases in Denmark, from December 2021 to January 2022. The secondary attack rate (SAR) at seven days was estimated as 29% and 39% in households infected with Omicron BA.1 and BA.2, respectively. SAR was lowest in those index cases who were booster vaccinated compared to fully vaccinated and unvaccinated people. The study reported lower transmissibility in both BA.1 and BA.2 households when the index case was booster-vaccinated rather than fully vaccinated, with an odds ratio (OR) of 0.77 (95% confidence interval [CI]: 0.70 to 0.88) and 0.79 (95% CI: 0.64 to 0.98) for BA.1 and BA.2, respectively. There was no statistically significant difference in transmissibility in BA.1 households between unvaccinated and fully vaccinated index cases (OR: 0.93, 95% CI: 0.80 to 1.08). There was also no statistically significant difference in transmissibility between unvaccinated and fully vaccinated index cases in BA.2 households for unvaccinated index cases (OR: 1.21, 95% CI: 0.97 to 1.50) (Lyngse et al. 2022a).

Allen et al. (2022a) conducted a contact-tracing study of 51,281 SARS-CoV-2 positive people in England (13,680 with Omicron), between 5 and 11 December 2021, and found that SARs were consistently higher for Omicron than Delta for every stratum of vaccination dose for index cases or contacts.

For Delta cases, SARs were lowest among index cases who were booster-vaccinated in the household (6.2%, 95% CI: 5.3% to 7.1%) and non-household setting (3.1%, 95% CI: 2.1% to 4.2%), compared to unvaccinated people in the household setting (11.8%, 95% CI: 11.4% to 12.3%) and non-household setting (4.9%, 95% CI: 4.0% to 5.8%). The impact of index case vaccination on transmission rates for Omicron cases was considerably attenuated compared to Delta, with secondary transmission rates marginally lower for booster-vaccinated index Omicron cases (12.4%, 95% CI: 10.9% to 13.8%) compared to less than 3 doses (14.9%, 95% CI: 13.1% to 16.8%) or unvaccinated groups (15.8%, 95% CI: 14.7% to 17.0%) for all comparisons. In non-household settings, SAR was lower for Omicron cases in index cases who were vaccinated; the SAR was 8.8% (95% CI: 7.2% to 10.4%) for those who were unvaccinated, 7.5% (95% CI: 6.9% to 8.0%) for those who were fully vaccinated and 7.1% (95% CI: 5.7% to 8.4%) for those who were booster vaccinated (Allen et al. 2022a).

In addition, the proportion of index cases resulting in residential clustering was twice as high for Omicron (16.1%) compared to Delta (7.3%) (Allen et al. 2022a). The risk ratio of household clustering found that the overall risk ratio was 3.54 (95% CI: 3.29 to 3.81) for Omicron compared to Delta variants. Furthermore, for each of vaccination status there was an increased risk of household clustering for Omicron compared to Delta variants, most notably among index cases who were ≥14 days post their third vaccine dose, with a risk ratio of household clustering of 6.81 comparing Omicron and Delta variants (95% CI: 4.91 to 9.46) (Allen et al. 2022a).

Another contact-tracing study by Jalali et al. (2022), of 1,122 index cases and 2,169 household contacts in Norway, found an overall higher household ten-day SAR for the Omicron variant (51%, 95% CI: 48% to 54%) compared to the Delta variant (36%, 95% CI: 33% to 40%), with a relative risk of 1.41 (95% CI: 1.27 to 1.56). Index cases who were booster vaccinated were found to have a considerably higher risk (relative risk: 4.34; 95% CI: 1.52 to 25.16) of transmitting SARS-CoV-2 to their household contacts with Omicron compared to Delta. A similar trend was observed when the index case was unvaccinated or fully vaccinated, although the relative risks were lower (unvaccinated relative risk: 1.51, 95% CI: 1.30 to 1.77; fully vaccinated relative risk: 1.44, 95% CI: 1.24 to 1.70). There was not a significant increase in transmissibility in Omicron index cases who were partially vaccinated, compared to Delta (relative risk: 1.05, 95% CI: 0.76 to 1.52). Fully vaccinated index cases had a similar risk as unvaccinated index cases in Omicron transmission to their adult household members (relative risk: 1.04; 95% CI: 0.79 to 1.49). The same pattern was observed for the booster-vaccinated versus unvaccinated index cases (relative risk: 0.99; 95% CI: 0.68 to 1.49). In contrast, booster-vaccinated index cases with Delta had an 80% lower risk of transmission (0.18; 95% CI: 0.01 to 0.70) relative to unvaccinated index cases (Jalali et al. 2022).

Vaccine effectiveness

The effectiveness of vaccines in reducing infection for booster-vaccinated adult contacts was lower for Omicron (45%; 95% CI: 26% to 57%) compared to Delta (65%; 95% CI: 42% to 80%) but higher than for fully vaccinated adults (Jalali et al. 2022).

Brandal et al. (2021) conducted a cohort study of 110 people in Norway who attended a party, including someone who had recently travelled to South Africa and tested positive for Omicron (following a targeted exploration due to travel) in the days following the party. Most of the attendees (96%) were fully vaccinated with two vaccine doses (but no booster doses). The cohort was tested for Omicron in the 17 days following the party: 59% were confirmed cases and 14% were probable cases of Omicron. The total attack rate for the Omicron variant was 74% (Brandal et al. 2021). Although this study didn't compare vaccinated people with unvaccinated, or levels of vaccination, it was included as it provided transmission data for the Omicron variant in fully vaccinated people.

1.1.2 Summary of the evidence for Omicron transmission and vaccine effectiveness

Evidence from the current review supports the findings of the study included in the previous review by Lyngse et al. (2021) that booster-vaccinated index cases transmit Omicron and Delta variant SARS-CoV-2 less than fully vaccinated index cases, who transmit less than unvaccinated index cases (Allen et al. 2022a, Brandal et al. 2021, Jalali et al. 2022, Lyngse et al. 2022a). Furthermore, one of the studies included in this review found that the same is true for both subvariants of Omicron (BA.1 and BA.2) (Lyngse et al. 2022a).

The study by Lyngse et al. (2021) in the previous review and the studies identified in this review found evidence that the risk of transmission for index cases with Omicron was higher compared with Delta variant SARS-CoV-2, in those of all vaccination exposure statuses (Allen et al. 2022a, Jalali et al. 2022, Lyngse et al. 2021).

The evidence included in this review and the previous review also suggests that transmission was significantly less likely to contacts who had received booster vaccines compared to contacts who were fully vaccinated or partially vaccinated (Allen et al. 2022a, Lyngse et al. 2021).

1.2 Evidence for the Delta variant

There were 10 studies in the previous review (Allen et al. 2022b, Clifford et al. 2021, de Gier et al. 2021a, Eyre et al. 2022, Hsu et al. 2021, Kang et al. 2022, Lyngse et al. 2021, Martinez-Baz et al. 2021, Ng et al. 2021, Singanayagam et al. 2021) which suggested fully vaccinated cases transmitted Delta variant SARS-CoV-2 less than unvaccinated cases. Two of these studies suggested that vaccine effectiveness against transmission of the Delta variant dropped substantially over time, though no studies in the update assessed this. Additionally, evidence from 9 studies in the previous review (Clifford et al. 2021, Eyre et al. 2022, Hsu et al. 2021, Lyngse et al. 2021, Lyngse et al. 2022b, Martinez-Baz et al. 2021, Ng et al. 2021, Singanayagam et al. 2021, Yi et al. 2022) suggested that index cases typically transmitted SARS-CoV-2 to fully vaccinated contacts less than unvaccinated contacts.

Two studies included in this update looked at the difference in transmission of the Delta variant SARS-CoV-2 alone from vaccinated and unvaccinated index cases (Andrejko et al. 2021, Sriraman et al. 2022).

Andrejko et al. (2021) found that the odds of cases status were lower for both partially (OR: 0.30, 95% CI: 0.15 to 0.43) and fully vaccinated (OR: 0.25, 95% CI: 0.15 to 0.43) participants relative to unvaccinated participants. The study also reported that of the odds ratio of participants with case status was 3.02 (95% CI: 1.75 to 5.22) when high-risk exposures occurred with household members (versus other contacts), 2.10 (95% CI: 1.05 to 4.21) when exposures occurred indoors (versus outdoors), and 2.15 (95% CI: 1.27 to 3.67) when exposures lasted \geq 3 hours (versus shorter durations) among unvaccinated and partially-vaccinated individuals; excess risk associated with such exposures was mitigated among fully-vaccinated individuals.

A prospective, observational study of 92 index cases in India (pre-print) by Sriraman et al. (2022) reported that the median household infection rate (HHR: defined as the number of confirmed positive members in the household at enrolment + number of new positive members at follow-up + number of new positive members at final telephone follow-up)/total number of individuals living in the same household) was significantly higher in people partially vaccinated with AstraZeneca (median HHR: 67%) and fully vaccinated with AstraZeneca (median HHR: 67%) and fully vaccinated with (Sriraman et al. 2022).

1.2.1 Summary of the evidence for Delta transmission

Overall, evidence from 10 studies from the previous review (Allen et al. 2022b, Clifford et al. 2021, de Gier et al. 2021a, Eyre et al. 2022, Hsu et al. 2021, Kang et al. 2022, Lyngse et al. 2021, Martinez-Baz et al. 2021, Ng et al. 2021, Singanayagam et al. 2021) and one of the studies in this review (Andrejko et al. 2021) suggested fully vaccinated cases transmitted Delta variant SARS-CoV-2 less than unvaccinated cases. However, the one new study identified in this review did not find a significant difference in the risk of transmission amongst vaccinated and unvaccinated people with the Delta variant (Sriraman et al. 2022).

Two studies from the previous review suggested that vaccine effectiveness against transmission of the Delta variant dropped substantially over time. Additionally, evidence from 9 studies from the previous review (Clifford et al. 2021, Eyre et al. 2022, Hsu et al. 2021, Lyngse et al. 2021, Lyngse et al. 2022b, Martinez-Baz et al. 2021, Ng et al. 2021, Singanayagam et al. 2021, Yi et al. 2022) suggested that index cases typically transmitted SARS-CoV-2 to fully vaccinated contacts less than unvaccinated contacts.

1.3 Evidence for pre-Delta variants

Evidence from 15 studies from the previous review (Allen et al. 2021, Braeye et al. 2021, de Gier et al. 2021b, Harris et al. 2021a, Harris et al. 2021b, Layan et al. 2022, Meyer et al. 2021, Prunas et al. 2022, Shah et al. 2021, Allen et al. 2022b, Bobdey et al. 2021, Clifford et al. 2021, Hsu et al. 2021, Martinez-Baz et al. 2021, Ng et al. 2021) suggested that fully vaccinated index cases transmitted pre-Delta variant and Wild-type SARS-CoV-2 to their contacts less than unvaccinated index cases, and this reduction was substantial (e.g. >50% reduction in transmission) in many studies. No new evidence was identified in this review.

2. New evidence on viral load in those who develop COVID-19 infection after being vaccinated (Table 2)

In this update, we identified 11 additional observational studies that compared viral loads (predominantly using Ct values) between vaccinated and unvaccinated COVID-19 cases. Six were pre-prints (Boucau et al. 2022, Fall et al. 2022, Kislaya et al. 2022a, Lyngse et al. 2022a, Qassim et al. 2022, Sriraman et al. 2022). Of 11 studies, three studies were judged to be high quality (Lyngse et al. 2022a, Migueres et al. 2022, Qassim et al. 2022), six of medium quality (Accorsi et al. 2022, Boucau et al. 2022, Fall et al. 2022, Kislaya et al. 2022a, Sriraman et al. 2022, Williams et al. 2021) and two were of low quality (Kissler et al. 2021, Barbosa et al. 2022). Of these, nine were cohort studies (Barbosa et al. 2022, Boucau et al. 2022, Fall et al. 2022, Kissler et al. 2021, Lyngse et al. 2022a, Migueres et al. 2022, Qassim et al. 2022, Sriraman et al. 2022, Williams et al. 2021), and 2 were case-control studies (Accorsi et al. 2022, Kislaya et al. 2022a) . One of the studies provided data from the UK (Williams et al. 2021), 4 from the USA (Accorsi et al. 2022, Boucau et al. 2022, Fall et al. 2022, Kissler et al. 2021), 3 from Europe (Kislaya et al. 2022a, Lyngse et al. 2022a, Migueres et al. 2022), 2 from Asia (Qassim et al. 2022, Sriraman et al. 2022) and one from Brazil (Barbosa et al. 2022).

All studies were conducted between November 2020 and February 2022.

Three studies looked at the Omicron variant (Fall et al. 2022, Lyngse et al. 2022a, Qassim et al. 2022), three looked at both Omicron and Delta variants (Accorsi et al. 2022, Boucau et al. 2022, Kislaya et al. 2022a), one looked at the Delta variant (Sriraman et al. 2022), two looked at both Delta and Alpha variants (Kissler et al. 2021, Migueres et al. 2022), one looked at the Alpha variant (Williams et al. 2021), and one study included data without reporting the variant (Sriraman et al. 2022).

Table 2 shows a summary of all viral load studies, including studies from both this update (with black text) and from the previous review (in grey text), and Supplementary Table 2 shows full information for all viral load studies.

2.1 Evidence for the Omicron variant

Two studies included in the previous review compared the viral loads of Omicron and Delta variant cases (Puhach et al. 2022, Lyngse et al. 2021), though neither study reported the difference in Ct value between vaccinated and unvaccinated cases.

Six studies included in this update compared the viral load of Omicron in vaccinated and unvaccinated people (Accorsi et al. 2022, Boucau et al. 2022, Fall et al. 2022, Kislaya et al. 2022a, Lyngse et al. 2022a, Qassim et al. 2022).

2.1.1 Viral load (Ct values)

A retrospective test-negative case-control analysis conducted in the USA measured median Ct values for three viral genes, stratified by variant and vaccination status, in 23,391 people with a positive SARS-CoV-2 test (Accorsi et al. 2022). Median Ct values were significantly higher (q-value < 0.001), indicating lower viral load, in cases who were booster vaccinated versus those who were fully vaccinated, for both Omicron and Delta (Omicron N gene: 19.35 versus 18.52; Omicron ORF1ab gene: 19.25 versus 18.40; Delta N gene: 19.07 versus 17.52; Delta ORF1ab gene: 18.70 versus 17.28; Delta S gene: 23.62 versus 20.24). Among Omicron cases, median Ct values were slightly higher, indicating lower viral load, in samples from booster-vaccinated people versus unvaccinated people for the ORF1ab gene (19.25 versus 18.58) but not for the N gene (19.35 versus 18.71). Among Delta cases, median Ct values of the N, ORF1ab, and S genes were slightly higher (indicating lower viral load) in samples from people who were booster vaccinated versus unvaccinated (N gene: 19.07 versus 18.28; ORF1ab gene: 18.70 versus 17.84; S gene: 23.62 versus 19.58) (Accorsi et al. 2022).

A pre-print by Fall et al. (2022) reported no statistically significant difference when Ct values were compared between vaccinated and unvaccinated patients from: Omicron vaccinated groups (n = 235), Omicron unvaccinated (n = 170), Delta vaccinated (n = 240), and Delta unvaccinated (n = 411) groups (Fall et al. 2022).

Kislava et al. (2022a) conducted a case-case study in Portugal of 4,898 people aged 12 years and older with Omicron and 8,245 people aged 12 years and older with Delta variants. For patients aged 50 years and older, of which 18% were booster vaccinated, no statistically significant differences in mean Ct values by variant or vaccination status were observed. They did not find a significant mean difference in Ct values between these two variants for unvaccinated (-0.002, 95% CI: -0.6 to 0.6), partially vaccinated (-1.1, 95% CI: -2.6 to 0.36) or fully vaccinated people (-0.01, 95% CI: -0.2 to 0.2).

Viral load (Ct values): Omicron subvariants

A retrospective cohort study by Lyngse et al. (2022a) of 8,541 primary household cases in Denmark assessed the transmission of two subvariants of Omicron (BA.1 and BA.2) to

household members. The study reported that the distribution of sample Ct values for unvaccinated index cases was higher overall for BA.2 cases than for BA.1 cases. This was not the case for fully vaccinated and booster-vaccinated individuals, where the distribution appeared to be similar.

A similar cross-sectional study of 156,202 people in Qatar also investigated the effects of vaccination on the Ct values of Omicron subvariants BA.1 and BA.2 (Qassim et al. 2022). They found that compared to BA.1, BA.2 was associated with a lower Ct value (-3.53, 95% CI: -3.46 to -3.60). Ct values decreased with time since second and third vaccinations, following the established pattern of waning vaccine effectiveness. Ct values were highest for those who received their boosters in the month preceding the RT-qPCR test: 0.86 cycles (95% CI: 0.72 to 1.00) higher than for unvaccinated persons (Qassim et al. 2022).

2.1.2 Viral load (Ct values, time since vaccination)

Considering time since completion of primary vaccination, Kislaya et al. (2022a) observed statistically significant differences between Delta and Omicron cases only for cases with less than 113 days since complete primary vaccination (mean difference: -0.70; 95% CI: -1.13 to -0.28), indicating slightly lower Ct (higher viral loads) in Omicron cases. There were no statistically significant differences between Delta and Omicron for cases more than 113 days since complete primary vaccination (Kislaya et al. 2022a).

In the pre-print mentioned above by Fall et al. (2022), when the Ct analysis was correlated to the days from the onset of symptoms for symptomatic patients, no significant differences were detected between Omicron and Delta, considering fully vaccinated, boosted, and unvaccinated cases separately. The authors concluded that there were no significant differences in viral RNA loads between Omicron and Delta infected individuals (Fall et al. 2022).

2.1.3 Viral load (time to viral clearance)

A pre-print by Boucau et al. (2022) reported on how Omicron and Delta variants and vaccination status impact shedding of viable virus in an American longitudinal cohort study of 56 non-severely symptomatic patients with COVID-19. Viral load decay and time to negative PCR (time to PCR conversion) did not differ between participants infected with Omicron versus Delta (hazard ratio [HR]: 0.85, 95% CI: 0.44 to 1.61). Duration of shedding of viable virus, as measured by time to culture conversion, was also similar by variant (HR: 0.86, 95% CI: 0.47 to 1.58), with a median time to culture conversion of 6 days in both groups (IQR 4 to 8 days). In the overall cohort, there was no significant difference in time to PCR conversion (p = 0.08) or culture conversion (p = 0.57) by vaccination status.

2.1.4 Summary of the evidence for Omicron viral load

Evidence from 2 studies in the previous review (Lyngse et al. 2021, Puhach et al. 2022) suggests there is little difference between the Ct values and genome copy numbers of Omicron and Delta variant SARS-CoV-2 cases, though infectious viral loads may be smaller in Omicron cases. This is supported by 3 studies in this current review (Fall et al. 2022, Kislaya et al. 2022a, Boucau et al. 2022). However, a large study found that median Ct values were significantly higher in cases with booster doses versus cases who were fully vaccinated, for both Omicron and Delta, and between individuals who were booster vaccinated and unvaccinated (Accorsi et al. 2022), and another study found slightly higher

viral loads in Omicron compared to Delta for those cases with less than 113 days since complete primary vaccination (Kislaya et al. 2022a).

Two studies in this review reported Ct values in the Omicron subtypes BA.1 and BA.2 (Lyngse et al. 2022a, Qassim et al. 2022). One study found that viral load was overall higher for BA.2 cases than for BA.1 cases in unvaccinated people, but this was not the case for fully vaccinated and booster-vaccinated individuals (Lyngse et al. 2022a). The other study also reported viral load as being higher for BA.2 cases and that Ct values were highest for those who received their boosters in the month preceding the PCR test compared to unvaccinated cases (Qassim et al. 2022).

2.2 Evidence for the Delta variant

2.2.1 Viral load (Ct values)

Evidence from 25 studies from the previous review (Acharya et al. 2021, Chia et al. 2021, Christensen et al. 2022, Elliott et al. 2021, Eyre et al. 2022, Griffin et al. 2021, Hirotsu et al. 2021, Hsu et al. 2021, Kale et al. 2021, Kang et al. 2022, Kerwin et al. 2021, Kislaya et al. 2022b, Levine-Tiefenbrun et al. 2021a, Levine-Tiefenbrun et al. 2022, Luo et al. 2021a, Lyngse et al. 2022b, Magalis et al. 2021, Pouwels et al. 2021, Puhach et al. 2022, Riemersma et al. 2021, Salvatore et al. 2021, Servellita et al. 2022, Siddle et al. 2022, Singanayagam et al. 2021, Yi et al. 2022) suggests mixed evidence for a difference in viral load between fully vaccinated and unvaccinated cases, with 17 studies suggesting no difference and 8 studies suggesting higher Ct values (lower viral load) in fully vaccinated cases.

A further three studies have been included in this update, which report on Ct levels in vaccinated and unvaccinated Delta cases (Barbosa et al. 2022, Migueres et al. 2022, Sriraman et al. 2022).

A study of 1,059 vaccinated healthcare workers in Brazil was published in a letter by Barbosa et al. (2022) and did not observe a significant difference in the viral load regardless of vaccine type or number of doses (Barbosa et al. 2022).

A prospective study in France by Migueres et al. (2022) reported that the nasopharyngeal viral loads of unvaccinated patients infected with the Delta variant were greater than in fully vaccinated patients (median 7.1 versus 6.64, p < 0.001). The difference was similar for the Alpha variant but not significant (the authors suggest that this is due to the small sample size).

Another prospective study of 92 people with COVID-19 in India (pre-print) by (Sriraman et al. 2022) found no significant difference in the expelling pattern (high-risk emitters [people expelling >1000 viral copy numbers in 30 minutes], medium-risk emitters [A viral copy number of 100-999] and low-risk emitters [< 100 copy numbers] of SARS-CoV-2) between partial, full and unvaccinated individuals, suggesting similar transmission risk. In addition, the viral load data showed that only patients in the partially and fully vaccinated AstraZeneca groups had a statistically significant reduction in viral load at follow-up (8 to 12 days after COVID-19 diagnosis), compared to other vaccines and unvaccinated cases.

Overall, evidence from 28 studies (25 studies from the previous review (Acharya et al. 2021, Chia et al. 2021, Christensen et al. 2022, Elliott et al. 2021, Eyre et al. 2022, Griffin et al. 2021, Hirotsu et al. 2021, Hsu et al. 2021, Kale et al. 2021, Kang et al. 2022, Kerwin et al. 2021, Kislaya et al. 2022b, Levine-Tiefenbrun et al. 2021a, Levine-Tiefenbrun et al. 2022, Luo et al. 2021a, Lyngse et al. 2022b, Magalis et al. 2021, Pouwels et al. 2021, Puhach et al. 2022, Riemersma et al. 2021, Salvatore et al. 2021, Servellita et al. 2022, Siddle et al. 2022, Singanayagam et al. 2021, Yi et al. 2022), and three studies from this update (Barbosa et al. 2022, Migueres et al. 2022, Sriraman et al. 2022), suggests mixed evidence for a difference in viral load between fully vaccinated and unvaccinated cases, with 17 studies suggesting no difference and 11 studies suggesting higher Ct values (lower viral load) in fully vaccinated cases.

2.2.2 Viral load (Ct values, time since vaccination)

In the previous preview, evidence from 2 studies (Levine-Tiefenbrun et al. 2021a), (Levine-Tiefenbrun et al. 2022) suggested that although Ct values are higher in fully and boostervaccinated cases compared with unvaccinated cases (lower viral load) soon after vaccination, this difference drops quickly, with Ct values becoming similar between 61 and 120 days after vaccination.

2.2.3 Viral load (time to viral clearance)

Evidence from 4 studies in the previous review (Hagan et al. 2021, Kang et al. 2022, Salvatore et al. 2021, Singanayagam et al. 2021) suggested that there was not a large or statistically significant difference in the time to viral clearance between fully vaccinated and unvaccinated cases.

Two studies investigating viral clearance were included in this update (Kissler et al. 2021, Sriraman et al. 2022).

SARS-CoV-2 viral dynamics were investigated in a prospective, longitudinal study, published in a letter by (Kissler et al. 2021), with 37 vaccinated and 136 unvaccinated people. Vaccinated individuals exhibited faster clearance compared to unvaccinated (mean: 5.5 days [95% CI: 4.6 to 6.5] versus 7.5 days [95% CI: 6.8 to 8.2]).

A prospective, observational study of 92 people with COVID-19 in India (pre-print) by Sriraman et al. (2022) found that among the vaccinated groups, the patients in the fully vaccinated Covaxin group (Bharat Biotech) had significantly higher mask positivity (proportion of patients expelling the virus) at 8 days (90%) compared to the partially and fully AstraZeneca vaccinated groups, suggesting that Covaxin patients may be clearing the virus slower than the AstraZeneca vaccinated groups and unvaccinated.

Overall, evidence from four studies in the previous review (Hagan et al. 2021, Kang et al. 2022, Salvatore et al. 2021, Singanayagam et al. 2021) did not suggest large or statistically significant differences in the time to viral clearance between fully vaccinated and unvaccinated cases. However, evidence from the 2 studies in this update suggest that vaccinated individuals exhibit faster viral clearance compared to unvaccinated (Kissler et al. 2021, Sriraman et al. 2022).

2.2.4 Infectious viral load (cytopathic effects)

Evidence from 6 studies from the previous review (Hagan et al. 2021, Luo et al. 2021a, Peña-Hernández et al. 2022, Puhach et al. 2022, Riemersma et al. 2021, Salvatore et al. 2021), suggested there was little difference in cytopathic effects between fully vaccinated and unvaccinated cases. No new evidence was identified in this review for this outcome.

2.3 Evidence for pre-Delta variants

From 27 studies from the previous review (Adamson et al. 2021, Abu-Raddad et al. 2022, Bailly et al. 2022, Blanquart et al. 2021, Boschi et al. 2021, Brunner-Ziegler et al. 2022, Costa et al. 2022, Emary et al. 2021, Eyre et al. 2022, Griffin et al. 2021, Hsu et al. 2021, Ioannou et al. 2021, Jacobson et al. 2022, Kislaya et al. 2022b, Kolobukhina et al. 2021, Lumley et al. 2021, Luo et al. 2021a, McEllistrem et al. 2021, Mostafa et al. 2021, Muhsen et al. 2021, Pajon et al. 2021, Pouwels et al. 2021, Regev-Yochay et al. 2021, Servellita et al. 2022, Smith et al. 2022, Tande et al. 2021, Thompson et al. 2021), there was evidence suggesting fully vaccinated cases had higher Ct values than unvaccinated cases (suggesting a lower viral load).

One study was identified in this update, which involved a retrospective analysis of test trending data of arrivals into the UK, and reported mean Ct values of positive cases from vaccinated (n = 274) and unvaccinated (n = 2,417) individuals as being 25.42 and 25.55, respectively, indicating no significant difference in the viral loads between these two groups (Williams et al. 2021).

3. Inequalities

There was little evidence availably to explore inequalities through variations across populations and subgroups, for example cultural variations or differences between ethnic, social, or vulnerable groups, either in the previous review or this update. As such, it was not possible to examine inequalities in this report.

4. Limitations

The source of evidence in this review included peer-reviewed and pre-print articles. We did not conduct an extensive search of other sources (such as websites of public health organisations).

All studies were observational, comparing people who were vaccinated with those who were not. Therefore, there is a high risk in all studies that factors other than vaccination affected the results. This includes factors such as behaviour (including test seeking behaviour and behaviours likely to alter the risk of SARS-CoV-2 transmission), individual characteristics (such as age, sex, and deprivation), and COVID-19 characteristics (such as variant and symptom status). Partly due to this heterogeneity and partly due to a lack of evidence, we were unable to assess how the risk of onward transmission varied with different vaccine

types and baseline community transmission levels. Few studies (4 of 43 in the previous review, 5 of 17 in this update) were rated as high quality using the QCC tool, largely because few studies accounted for these risks well.

Most studies were heterogeneous, in terms of their location, prevalence of COVID-19 in the community, prevalence of past infections, dominant variant, background mitigations in place to limit transmission (including both local restrictions and personal protective measures), vaccination status of contacts, and availability of the vaccine to different groups, as well as the demographics of the index cases, household members and other close contacts. This makes direct comparison between studies and specific vaccines difficult. However, there were four studies offering medium to high quality evidence from the UK for the Delta variant (Allen et al. 2022a, Allen et al. 2022b, Eyre et al. 2022, Williams et al. 2021).

As with all reviews, the evidence identified may be subject to publication bias, whereby null or negative results are less likely to have been published by the authors. Ten of the 25 studies identified in this update were pre-prints and should be treated with caution as they have not been peer reviewed or subject to publishing standards and may be subject to change. This is in addition to 19 pre-prints or non-peer reviewed reports of the 43 studies identified in the previous review, although 2 of these have since been published (Gazit et al. 2021a, Luo et al. 2021b). In addition, our rapid review is limited by the fact that we are reviewing evidence from an emerging field that spans less than 1 year, and only 2 months for the currently dominant Omicron variant. Studies conducted in the COVID-19 context are conducted at pace with the aim to provide evidence in a timely manner, which sometimes impacts on the quality of the studies, both in term of design (especially limited statistical analyses) and reporting (insufficient detail). There is currently little evidence for the recently identified Omicron variant (Lyngse et al. 2021, Puhach et al. 2022).

5. Conclusion

The main conclusions from the previous review were not changed from the inclusion of 17 additional studies in this update.

There was evidence that fully and booster-vaccinated cases transmit SARS-CoV-2 less than unvaccinated cases, particularly for pre-Delta and Wild-type variants, and there was evidence suggesting that this difference is reduced with increasing time after the vaccine dose, particularly for the Delta and Omicron variants. The results from viral load studies are broadly supportive of these results, with most pre-Delta studies showing fully vaccinated cases have larger Ct values or lower viral loads than unvaccinated cases, and most Delta and Omicron studies showing no clear difference in Ct values between fully vaccinated and unvaccinated cases.

The transmission studies that reported Omicron data included in this update suggested that fully- and booster- vaccinated index cases can transmit both Omicron and Delta variant SARS-CoV-2 less than unvaccinated index cases, with the risk of transmission of Omicron being higher compared with the Delta variant SARS-CoV-2.

In almost all included studies (transmission and viral load) there is a high risk that factors other than vaccination may have affected the results, which may have biased the results in either direction. Most studies were also highly heterogeneous, so caution must be used when comparing results between different studies. Partly because of this heterogeneity, there was insufficient evidence to examine whether transmission varies by vaccine type or at different baseline community transmission levels.

6. Research needed

Randomised controlled trials of vaccination assessing transmission to household members or other close contacts would help us to understand the true vaccine effectiveness against transmission of SARS-CoV-2, and from the previous review, we are aware of 2 ongoing RCTs, 1 in the US (NCT04811664, estimated publication date December 2021) and 1 in the UK (NCT04750356, estimated publication date December 2024), that could help estimate this. A cross-sectional school-based study to investigate SARS-CoV-2 transmission dynamics and the impact of different variants among confirmed cases and classmates is also ongoing (Bordas et al. 2022). These studies are described in Supplementary Table 3. The results of these trials have not yet been published as of 25 May 2022.

7. Acknowledgments

We would like to thank colleagues within the Public Health Advice, Guidance and Expertise function who either reviewed or input into aspects of the previous or this updated review, especially Helen McAuslane and Mario Aramouni. Also, thanks to Welsh Government and Public Health Wales stakeholders Simon Rolfe and Catherine Moore for their support of this work. We would also like to thank Sean Harrison and Rachel Clarke from the UK Health Security Agency (UKHSA), who had considerable contributions to the report.

Funding statement:

Health Technology Wales was funded for this work by the Wales Covid-19 Evidence Centre, itself funded by Health and Care Research Wales on behalf of Welsh Government.

8. Summary Tables

Table 1. Summary of key findings from transmission studies

	Country,	Contact				Effect estimate (95% CI)			
Study	time, dominant variant	type, vaccination status	Vaccine	Outcome	Unvaccinated	Partially Vaccinated	Fully Vaccinated	Booster vaccinated	
Vaccination of <i>inde</i>	x⁴/primary⁵	cases on SA	RS-CoV-2 trans	mission to household contacts (effect	estimates by ir	idex case vaccin	ation status)		
Allen (Allen et al. 2021)	UK, Mar- May 2021, Alpha	Household members, not stated	AstraZeneca or Pfizer	OR for transmission	Reference	0.94 (0.81 to 1.08)	0.76 (0.44 to 1.31)		
Allen /(Allen et al. 2022b)	UK, Mar-Jun 2021, Alpha (40%), Delta (43%)	Household members, not stated	Any	OR for transmission	Reference	0.94 (0.84 to 1.05)	0.73 (0.58 to 0.90)		
Bobdey (Bobdey et al. 2021)	India, Feb- Apr 2021, NR	Hospital dormitory residents, not stated	AstraZeneca	SAR	21.4%	4.3%	%		
	UK, Feb- Sept 2021,	Household	AstraZeneca		Reference	-7% (-60% to 29%)	35% (-26% to 74%)		
Clifford (Clifford et al.	Alpha	members, 75%	Pfizer	RR reduction for transmission	Reference	26% (-11% to 54%)	57% (5% to 85%)		
2021) D	UK, Feb- Sent 2021 vaccinated	unvaccinated or partially vaccinated	AstraZeneca		Reference	14% (-11% to 52%)	42% (14% to 69%)		
	Delta	P	Pfizer		Reference	9% (-16% to 49%)	31% (-3% to 61%)		
			Any	SAR	31%	29%	11%		

	Country,	Contact				Effect estim	nate (95% CI)				
Study	dominant variant	type, vaccination status	Vaccine	Outcome	Unvaccinated	Partially Vaccinated	Fully Vaccinated	Booster vaccinated			
					Reference	21% (9% to 33%)	71% (63% to 77%)				
	The Netherlands, Feb-May 2021,	,Household contacts, 96% unvaccinated	AstraZeneca	RR reduction for transmission	Reference	15% (4% to 26%)	58% (12% to 84%)				
de Gier (de Gier et al. 2021b)			Janssen		Reference	-	77% (6% to 94%)				
	Alpha		Moderna		Reference	51% (8% to 74%)	88% (50% to 97%)				
			Pfizer		Reference	26% (12% to 37%)	70% (61% to 77%)				
				SAR	22%	17%	13%				
		Household contacts,		RR reduction for transmission	Reference	46% (20% to 63%)	40% (20% to 54%)				
	The	unvaccinated		SAR (≥60 days after 2 nd dose)	22%	-	15%				
de Gier (de Gier et al. 2021a)	Netherlands, Aug-Sep 2021, Delta	,	Any	RR reduction for transmission (≥60 days after 2 nd dose)	Reference	-	55% (19% to 76%)				
	,	Hausshold		SAR	11%	6%	12%				
		Household contacts, 0% unvaccinated		RR reduction for transmission	Reference	38% (-2% to 62%)	63% (46% to 75%)				
								c,	SAR (≥60 days after 2 nd dose)	11%	-

	Country,	Contact					Effect estimate (95% CI)			
Study	dominant variant	type, vaccination status	Vaccine Outcome Ui		Unvaccinated	Partially Vaccinated	Fully Vaccinated	Booster vaccinated		
				RR reduction for transmis 2 nd dose)	RR reduction for transmission (≥60 days after 2 nd dose)		-	28% (-4% to 50%)		
		Hausshald	AstraZeneca	SAR		10.1%	5.7%			
Harris (Harris et al. 2021a. Harris et al.	UK, Jan-Feb 2021.	members,		OR for transmission		Reference	0.53 (0.43	to 0.63)		
2021b)	Alpha	100% unvaccinated	Pfizer	SAR		10.1%	6.2%			
				OR for transmission		Reference	0.51 (0.44 to 0.59)			
	Norway, 14 December			Omicron	SAR (95% CI)	0.57 (0.51 to 0.62)	0.42 (0.34 to 0.49)	0.51 (0.47 to 0.55)	0.46 (0.36 to 0.55)	
		Household members, 25%	mRNA vaccines or AstraZeneca		RR of transmission (95% CI)	Reference	1.01 (0.64 to 1.58)	1.04 (0.79 to 1.49)	0.99 (0.68 to 1.49)	
Jalali (Jalali et al. 2022)	20201 to 23 January 2022,			Delta	SAR (95% CI)	0.38 (0.33 - 0.42)	0.39 (0.29 to 0.51)	0.35 (0.31 to 0.40)	0.11 (0.02 to 0.29)	
	Omicron (> 90%)				RR of transmission (95% CI)	Reference	0.99 (0.51 to 1.64)	0.63 (0.46 to 0.89)	0.18 (0.01 to 0.70)	
				RR of transmission with 0 to Delta	Omicron compared	1.51 (1.30 - 1.77)	1.05 (0.76 to 1.52	1.44 (1.24 to 1.70)	4.34 (1.52 to 25.16)	
Layan (Layan et al.	Israel, Dec 2020-Apr	Household members,	50	SAR		40.7%	-	18.6%		
2022)	2021, Alpha	members, 82% unvaccinated	Pfizer	RR reduction for transmission		Reference	-	78% (30% to 94%)		

	Country,	Contact				Effect estimate (95% CI)			
Study dominan variant		type, vaccination status	Vaccine	Outcom	Outcome		Partially Vaccinated	Fully Vaccinated	Booster vaccinated
Lyngse (Lyngse et al. 2021)	Denmark, Dec 2021, Delta (81%), Omicron (19%)	Household members, not stated	AstraZeneca, Janssen, Moderna, Pfizer	OR for household transmis	sion	1.41 (1.27 to 1.57)		Reference	0.72 (0.56 to 0.92)
Dei		Household members, not stated		OR for household transmission	BA.1	0.93 (0.80 to 1.08)		Reference	0.77 (0.70 to 0.88)
	Denmark	nmark, Study ic 2021 to nuary vaccination of 22, index cases nicron A.2: 45%)	AstraZeneca, of Janssen, Moderna, Pfizer		BA.2	1.21 (0.97 to 1.50)		Reference	0.79 (0.64 to 0.98)
	Dec 2021 to			SAR	BA.1	34%		31%	22%
Lyngse (Lyngse et al. 2022a)	January 2022,				BA.2	43%		41%	34%
	Omicron (BA.2: 45%)			OR for suscentibility	BA.1	1.23 (1.09 to 1.40)		Reference	0.65 (0.58 to 0.73)
					BA.2	1.10 (0.92 to 1.32)		Reference	0.80 (0.67 to 0.94)
Meyer (Meyer et al. 2021)	Germany, Jan-Mar 2021, Alpha	Household members, 67% unvaccinated	Pfizer	SAR		67%	229	6	

	Country,	Contact					Effect estim	nate (95% CI)	
Study	dominant variant	type, vaccination status	Vaccine	Outcome		Unvaccinated	Partially Vaccinated	Fully Vaccinated	Booster vaccinated
Ng (Ng et al. 2021)	Singapore, Sep 2020- May 2021, Alpha	Household members,	Moderna, Pfizer	SAR	SAR		-	33.3%	
	Singapore, Sep 2020-	70% unvaccinated				25.8%	-	11.3%	
Prunas (Prunas et al.	May 2021, Delta			OR for household transmission		Reference	0.62 (0.22 to 1.69)	0.73 (0.38 to 1.40)	
Prunas (Prunas et al. 2022)	Israel, Jun 2020-Mar 2021, NR	Household members, NR	Pfizer	RR reduction for infectiousness		Reference	-	41% (10% to 73%)	
	Finland Dec	Household members		2	2 weeks	Reference	9% (-29% to 35%)	-	
Salo (Salo et al. 2021)	2020-Mar 2021, NR	(spouses), 100% unvaccinated	Pfizer, Moderna	RR reduction for transmission weeks after first dose	10 weeks	Reference	43% (22% to 58%)	-	
Shah* (Shah et al	UK, Dec	Household	AstraZanaca or	SAR per 100 person years		9.40	5.93 ¹	2.98	
2021)	2020-Mar 2021, NR	100% unvaccinated	Pfizer	HR for transmission		Reference	0.70 (0.63 to 0.78) ¹	0.46 (0.30 to 0.70)	
Sriraman (Sriraman et	India, July- Sept 2021	Household	Covaxin (Bharat Biotech)	Median household infection	straZeneca	20%	67%	88%	
al. 2022)	Delta (NR)	(NR) (NR)	Riotech), AstraZeneca	risk by vaccine Covaxin		2070	NR	50%	
Vaccination of <i>inde</i>	x cases on	SARS-CoV-2	transmission t	o close contacts (effect es	stimates by ir	ndex case vacc	ination status)		

	Country,	Contact			Effect estimate (95% CI)			
Study	dominant variant	type, vaccination status	Vaccine	Outcome	Unvaccinated	Partially Vaccinated	Fully Vaccinated	Booster vaccinated
Brandal (Brandal et al. 2021)	Norway, November and December 2021, Omicron	Close contacts in a party	BioNTech/Pfizer, Moderna	Total attack rate	NR	NR	74%	
			AstraZeneca		Reference	-3% (-10% to 2%)	8% (-79% to 63%)	
Braeye (Braeye et al.	Belgium, Jan-Jun	High risk contacts, 93% unvaccinated	Janssen	RR reduction for transmission	Reference	NA	27% (-23% to 62%)	
2021)	Alpha		Moderna		Reference	41% (23% to 57%)	52% (22% to 69%)	
			Pfizer		Reference	8% (-79% to 63%)	16% (8% to 22%)	
	The Netherlands,	Other close		SAR	11%	10%	9%	
De Gier (de Gier et al. 2021b) 2021, Alpha	Feb-May 2021, Alpha	contacts, 96% unvaccinated	Any	RR reduction for transmission	Reference	22% (9% to 33%)	22% (5% to 43%)	
Hsu (Hsu et al. 2021)	Germany, Dec 2020-		AstraZeneca,	SAR	37.8%	-	10.1%	
	Dec 2020- Aug 2021, Alpha (57%), Delta (40%)	Close contacts, not stated	Janssen, Moderna, Pfizer, Sinopharm, Sputnik	OR for transmission	Reference	-	0.21 (0.16 to 0.27)	

	Country,	^{y,} Contact				Effect estimate (95% CI)				
Study	dominant variant	type, vaccination status	Vaccine Outcome		Unvaccinated	Partially Vaccinated	Fully Vaccinated	Booster vaccinated		
Kang (Kang et al.	China, May-	Close		SAR			1.3%	2.5%	0.4%	
2022)	Jun 2021, Delta	contacts, 55% unvaccinated	NR	OR for transmission		Reference	-	0.35 (0.12 to 0.84)		
Martinez-Baz (Martinez-Baz et al. 2021)	Spain, Apr- Aug 2021, Alpha (52%), Delta (40%)	Close contacts, 47% unvaccinated	AstraZeneca, Moderna, Pfizer, Janssen	SAR			25%	19%	18%	
Vaccination of <i>ind</i>	ex cases on	SARS-CoV-2	transmission t	o household and oth	er conta	cts (effect	estimates by ir	ndex case vaccir	nation status)	
	England, 5-				Delta	household	11.8% (11.4% to 12.3%)	9.6% (8.8% to 10.4%)	10.0% (9.6% to 10.3%)	6.2% (5.3% to 7.1%)
Allen (Allen et al.	11 December 2021. Delta. Omicron accounted	Close contacts, 33.9% of Delta contacts	NR	SAR	Dona	Non- household	4.9% (4.0% to 5.8%)	4.7% (3.2% to 6.3%)	3.7% (3.4% to 4.1%)	3.1% (2.1% to 4.2%)
Allen (Allen et al. a 2022a) E E	for 26.6% cases in England during study	and 22.9% of Omicron contacts were unvaccinated			Omicron	Household	15.8% (14.7% to 17.0%)	14.9% (13.1% to 16.8%)	15.8% (15.1% to 16.5%)	12.4% (10.9% to 13.8%)
	period				Smooth	Non- household	8.8% (7.2% to 10.4%)	6.7% (4.6% to 8.9%)	7.5% (6.9% to 8.0%)	7.1% (5.7% to 8.4%)

	Country,	Contact				Effect estimate (95% CI)				
Study	dominant variant	type, vaccination status	Vaccine Outcome Ui		Unvaccinated	Partially Vaccinated	Fully Vaccinated	Booster vaccinated		
				RR Omicron vs Delta		Household	1.33 (1.23 to 1.44)	1.55 (1.34 to 1.81)	1.58 (1.50 to 1.67)	1.99 (1.66 to 2.39)
						Non- household	1.33 (1.23 to 1.44)	1.55 (1.34 to 1.81)	1.58 (1.50 to 1.67)	1.99 (1.66 to 2.39)
	England, Jan-Jul		AstraZeneca				46%	35%	28%	
2	2021, Alpha or Delta		Pfizer	SAR			46%	26%	21%	
			AstraZeneca	Rate ratio for transmissio	n		Reference	0.90 (0.86 to 0.94)	0.48 (0.30 to 0.78)	
			Pfizer				Reference	0.88 (0.85 to 0.91)	0.32 (0.21 to 0.48)	
Eyre (Eyre et al. 2022)	England, Jan-Jul	All contacts, 45% unvaccinated	AstraZeneca		2 v	veeks	-	-	52% (22% to 70%)	
	Alpha			Reduction in transmissior	12 1,	weeks	-	-	38% (-1% to 62%)	
			Pfizer	weeks after second dose	2 v	veeks	-	-	68% (52% to 79%)	
		Ρ	Pfizer		12	weeks	-	-	52% (29% to 67%)	
			AstraZeneca	Rate ratio for transmissio	n		Reference	0.95 (0.91 to 0.99)	0.76 (0.70 to 0.82)	

	Country,	Contact					Effect estim	nate (95% CI)	
Study	dominant variant	type, vaccination status	Vaccine	Outcome		Unvaccinated	Partially Vaccinated	Fully Vaccinated	Booster vaccinated
			Pfizer			Reference	0.83 (0.81 to 0.86)	0.50 (0.39 to 0.65)	
	England,		AstraZeneca		2 weeks	-	-	24% (18% to 30%)	
	Jan-Jul 2021 Delta			Reduction in transmission, weeks after second dose	12 weeks	-	-	2% (-2% to 6%)	
			Pfizer		2 weeks	-	-	50% (35% to 61%)	
					12 weeks	-	-	24% (20% to 28%)	
Singanayagam (Singanayagam et al. 2021)	UK, Sep 2020-Sep 2021, Delta	All contacts, not stated	AstraZeneca, Pfizer	SAR		23%	37%	25%	
Vaccination of cont	acts on SA	RS-CoV-2 tra	insmission to he	ousehold contacts (effect	estimates by	contact vaccin	ation status)		
	UK, Feb- Sept 2021,		AstraZeneca			Reference	3% (-38% to 39%)	26% (-39% to 73%)	
Clifford (Clifford et al.	Alpha	ha Household F members, 23% , Feb- unvaccinated A bt 2021, ita F	Pfizer	RR reduction for transmission		Reference	53% (7% to 83%)	71% (12% to 95%)	
2021) U S	UK, Feb- Sept 2021,		AstraZeneca			Reference	2% (-19% to 31%)	14% (-5% to 46%)	
	Delta		Pfizer			Reference	4% (-21% to 44%)	24% (-2% to 64%)	

	Country,	Contact			Effect estimate (95% CI)			
Study	dominant variant	type, vaccination status	Vaccine	Outcome	Unvaccinated	Partially Vaccinated	Fully Vaccinated	Booster vaccinated
			Any		Reference	23% (14% to 50%)	75% (72% to 78%)	
De Gier (de Gier et al. 2021b)	The Netherlands, Feb-May 2021, Alpha	Household ,contacts, 98% unvaccinated index cases	AstraZeneca		Reference	2% (-11% to 14%)	87% (77% to 93%)	
			Janssen	RR reduction for transmission	Reference	NA	12% (-71% to 54%)	
			Moderna		Reference	33% (-27% to 64%)	91% (79% to 97%)	
			Pfizer		Reference	-18% (-43% to 2%)	65% (60% to 70%)	
Gazit (Gazit et al.	Israel, Dec-	Household members, 8%		SAR	37.5%	41.7%	7.5%	
2021b, Gazit et al. 2021a)3	Mar 2021, NR	unvaccinated index cases	Pfizer	RR reduction for transmission	Reference	-	80% (74% to 85%)	
	Norway, 14 December 20201 to 23	Household		Omicron SAR	0.59 (0.53 to 0.64)	0.57 (0.48 to 0.66)	0.50 (0.46 to 0.54)	0.38 (0.31 to 0.44)
Jalali (Jalali et al. 2022)	January 2022, Omicron (> 90%)	members, 25% unvaccinated	mRNA vaccines or AstraZeneca	Delta SAR	0.47 (0.41 to 0.52)	0.34 (0.23 to 0.46)	0.32 (0.28 to 0.37)	0.20 (0.11 to 0.30)
Layan (Layan et al.	Israel, Dec 2020-Apr	Household members,	D()	SAR ²	75.0%	-	10.8%	
2022)	2021, Alpha	92% unvaccinated	PTIZEr	RR reduction for transmission ²	Reference	-	93% (83% to 97%)	

	Country,	Contact				Effect estimate (95% CI)				
Study	dominant variant	type, vaccination status	Vaccine	Outcome	Unvaccinated	Partially Vaccinated	Fully Vaccinated	Booster vaccinated		
Lyngse (Lyngse et al. 2022b)	Denmark, Jun-Nov 2021, Delta	Household members, 52% unvaccinated	AstraZeneca, Janssen, Moderna, Pfizer	SAR	28%	-	15%			
	Denmark,			SAR	29%		32%	25%		
Lyngse (Lyngse et al. 2021)	Dec 2021, Omicron	Household members, not	AstraZeneca, Janssen, Moderna, Pfizer	OR for transmission	1.04 (0.87 to 1.24)		Reference	0.54 (0.40 to 0.71)		
	Denmark,	stated		SAR	28%		19%	11%		
	Dec 2021, Delta			OR for transmission	2.31 (2.09 to 2.55)		Reference	0.38 (0.32 to 0.46)		
	Singapore,	Household		SAR	25.8%	-	11.3%			
Ng (Ng et al. 2021)	May 2021, Delta	70% unvaccinated	Moderna, Pfizer	OR for transmission	Reference	0.61 (0.33 to 1.12)	0.33 (0.17 to 0.63)			
Singanayagam (Singanayagam et al. 2021)	UK, Sep 2020-Sep 2021, Delta	Household members, not stated	AstraZeneca, Pfizer	SAR	38%	18%	25%			
Yi (Yi et al. 2022)	South Korea, Aug 2021, Delta	Household members, 39% unvaccinated	Pfizer	SAR	27.8%	25%	12.5%			
Vaccination of contacts on SARS-CoV-2 transmission to other contacts (effect estimates by contact vaccination status)										

	Country,	Contact			Effect estimate (95% CI)			
Study	dominant variant	type, vaccination status	Vaccine	Outcome	Unvaccinated	Partially Vaccinated	Fully Vaccinated	Booster vaccinated
			AstraZeneca		Reference	31% (27% to 35%)	55% (11% to 82%)	
Braeye (Braeye et al.	Belgium, Jan-Jun	High risk contacts, 100% unvaccinated index cases	Janssen	RR reduction for transmission	Reference	NA	57% (21% to 81%)	
2021)	2021, Alpha		Moderna		Reference	65% (57% to 81%)	85% (79% to 90%)	
			Pfizer		Reference	41% (37% to 45%)	74% (72% to 76%)	
De Gier (de Gier et al. 2021b)	The Netherlands Feb-May 2021, Alpha	Other close contacts, 98% unvaccinated index cases	Any	RR reduction for transmission	Reference	28% (17% to 38%)	79% (74% to 84%)	
			All			18%	14%	
			AstraZeneca			19%	18%	
	Spain, Apr-		Janssen	SAR	34%	-	21%	
Martinez-Baz (Martinez-Baz et al.	Aug 2021, Alpha	Close contacts. 47%	Moderna			14%	8%	
2021)	(52%), Delta	unvaccinated	Pfizer			17%	13%	
(40	(1070)	%)	AstraZeneca	RR reduction for transmission	Reference	41% (34% to 48%)	54% (48% to 60%)	
			Janssen			-	50% (42% to 57%)	

	Country,	^{/,} Contact		Vaccine Outcome		Effect estimate (95% CI)				
Study	dominant variant	type, vaccination status	Vaccine			Unvaccinated	Partially Vaccinated	Fully Vaccinated	Booster vaccinated	
			Moderna					66% (56% to 73%)	82% (78% to 86%)	
			Pfizer					57% (52% to 61%)	69% (66% to 72%)	
Vaccination of co	ontacts on SA	RS-CoV-2 tra	ansmission to h	ousehold and othe	r contacts	effect est	imates by cont	act vaccination s	status)	
				Risk of household clus vs Delta	Risk of household clustering aRR for Omicron vs Delta		3.19 (2.79 to 3.64)	4.09 (3.19 to 5.23)	3.56 (3.25 to 3.90)	6.81 (4.91 to 9.46)
	England, 5- 11 December	Close			Delta	Household	12.9% (12.4% - 13.5%)	10.6% (9.7% to 11.5%)	11.2% (10.8% to 11.6%)	7.6% (6.9% to 8.3%)
Allen (Allen et al. 2022a)	2021. Deita. Omicron accounted for 26.6% cases in	contacts, 47.8% of unvaccinated had Delta and 20.8% had	NR	SAR	Dona	Non- household	5.1% (3.4% - 6.8%)	6.0% (3.2% to 8.9%)	5.9% (5.1% to 6.7%)	3.0% (2.2% to 3.8%)
	England during study period	Omicron			Ominer	Household	15.9% (14.8% - 17.0%)	14.8% (12.8% to 16.8%)	18.3% (17.4% to 19.3%)	16.1% (14.5% to 17.7%)
					Umicron	Non- household	10.1% (7.4% to 12.8%)	7.4% (3.8% to 11.0%)	9.6% (8.4% to 10.9%)	7.3% (5.7% to 9.0%)

2	Country,	Contact				Effect estimate (95% CI)				
Study	dominant variant	type, vaccination status	Vaccine	Outc	Outcome		Unvaccinated	Partially Vaccinated	Fully Vaccinated	Booster vaccinated
				RR Omicron vs Delta		Household	1.23 (1.14 to 1.32)	1.40 (1.19 to 1.63)	1.64 (1.55 to 1.75)	2.13 (1.87 to 2.43)
						Non- household	1.99 (1.32 to 2.99)	1.22 (0.62 to 2.39)	1.64 (1.43 to 1.87)	2.43 (1.80 to 3.29)
Andrejko (Andrejko et al. 2021)	USA (California) February- November 2021, NR	High-risk exposures with household contacts and non- household contacts (75.3% unvaccinated)	Pfizer/BioNTech, Moderna, Janssen	OR		Reference	0.30 (0.15 to 0.43)	0.25 (0.15 to 0.43)		
	England, Jan-Jul		AstraZeneca	0.4.5			52%	32%	22%	
	2021, Alpha or Delta		Pfizer	SAK			52%	32%	17%	
Eyre (Eyre et al. 2022)	England, Jan-Jul	55% unvaccinated	AstraZeneca				Reference	0.94 (0.91 to 0.98)	0.40 (0.27 to 0.59)	
	2021, Alpha	index cases	Pfizer	Rate ratio for transmiss	sion		Reference	0.85 (0.82 to 0.88)	0.15 (0.11 to 0.21)	
			AstraZeneca				Reference	0.69 (0.66 to 0.72)	0.42 (0.38 to 0.45)	

	Country,	Contact				Effect estimate (95% CI)				
Study	dominant variant	type, vaccination status	Vaccine	Outcome	Unvaccinated	Partially Vaccinated	Fully Vaccinated	Booster vaccinated		
	England, Jan-Jul 2021, Delta		Pfizer		Reference	0.67 (0.65 to 0.69)	0.19 (0.16 to 0.23)			
Hsu (Hsu et al. 2021)	Germany, Dec 2020- Aug 2021, Alpha (57%), Delta (40%)	Close contacts, 50% unvaccinated	AstraZeneca, Janssen, Moderna, Pfizer, Sinopharm, Sputnik	OR for transmission	Reference	-	1.26 (0.90 to 1.77)			
Singanayagam (Singanayagam et al. 2021)	UK, Sep 2020-Sep 2021, Delta	All contacts, not stated	AstraZeneca, Pfizer	SAR	34%	15%	22%			
CI = confidence interva *These studies looked reducing transmission i ¹ These results are for b	il or credible i at all healthca from index ca both partially a	nterval, HR = h are workers, no ses with COVII and fully vaccin	azard ratio, NR = r t just those with a o D-19 ated participants	not reported, OR = odds ratio, RR = relative ris. confirmed SARS-CoV-2 infection, so these res	k, SAR = seconda ults include the ef	ary attack rate fect of vaccines on p	preventing COVIL	D-19 as well as on		
² These effect estimates are for contacts who were fully vaccinated and isolated compared with contacts who were unvaccinated and did not isolate										
³ Updated from previous report (pre-print was published or updated)										
⁴ Index case: first perso	n noticed by a	authorities that	makes them aware	e of an outbreak (patient 0)						
Studies with black text are from this updated search; studies with grey text are from a previous search										

Table 2. Summary of key findings from studies reporting viral load

							Effect estimat	e
Study	Country, time, dominant variant	Vaccine		Outcome		Unvaccinated (SD or IQR)	Vaccinated (SD or IQR)	Difference* (95% CI) or p value
Booster vaccinate	ed, Omicron variant							
	LISA and Puerto Rico, Dec 2021			ORF1ab gene	3 doses vs 2	-	3 doses: 19.25 (NR) 2 doses: 18.40 (NR)	0.85 (0.45 to 1.26)
Accorsi (Accorsi	– Jan 2022, Omicron (95%) of	95%) of nade up in study %	er and Difference in erna median Ct values		3 doses vs unvaccinated	18.58 (NR)	19.25 (NR)	0.67 (0.23 to 1.12)
et al. 2022)	56% of positive cases in study and Delta made up 44%			N gene	3 doses vs 2	-	3 doses: 19.35 (NR) 2 doses: 18.52 (NR)	0.83 (0.51 to 1.20)
					3 doses vs unvaccinated	18.71 (NR)	19.35 (NR)	0.65 (0.28 to 1.03)
Волсан (Волсан	USA, July 2021 to January 2022.	Johnson & Johnson/Janssen	Viral load decay and to PCR conversion)	d time to ne	gative PCR (time	Reference	1.16 (95% CI: 0.39, 3.45)	p = 0.80
et al. 2022)	In the study, 66% had Delta and 34% had Omicron	only one named but others also used	Duration of sheddin culture conversion)	g of viable v	virus (time to	Reference	1.36 (95% CI: 0.46, 4.03)	p = 0.57
Fall (Fall et al. 2022)	USA, 22 November to 31 December 2021, Omicron	Pfizer/BioNTech, Moderna, Johnson & Johnson/Janssen	Range of Ct values from onset of sympt	of samples oms	collected ≤ 5 days	11 to 33⁵	11 to 34 ⁵	NR
Kislaya (Kislaya et al. 2022a)	Portugal, 6 December to 26 December 2021, initially Delta, but then Omicron (50.8%)	Pfizer/BioNTech, Moderna, AstraZeneca Johnson & Johnson/Janssen	Range of Ct values more	in people a	ged 50 years or	11 to 29⁵	10 to 29.5⁵	NR
		Pfizer/BioNTech,	RA 1	Medi	an Ct value	27.02	27.65	NR
Lynase (Lynase	Denmark, Dec 2021 to January	Moderna,		Mear	n Ct value	27.20	27.72	NR
et al. 2022a)	2022, Omicron (BA.2: 45%)	AstraZeneca	D A 0	Medi	an Ct value	25.42	27.09	NR
		Jonnson & Johnson/Janssen	ВА.2	Mear	n Ct value	26.07	27.72	NR
Qassim (Qassim Q et al. 2022) B	Quatar, Dec 2021 – Feb 2022,	Pfizer Moderno	Ctivalue	≤1 m RT-q	onth before the PCR test	Reference	0.86 (0.72, 1.00)	p <0.001
	BA.2 (NR)			> 1 n RT-q	nonth before the PCR test	Reference	0.28 (0.14, 0.42)	p <0.001

							Effect estimat	e
Study	Country, time, dominant variant	Vaccine	Outcomes			Unvaccinated (SD or IQR)	Vaccinated (SD or IQR)	Difference* (95% CI) or p value
Fully vaccinated,	Omicron variant							
	USA and Puerto Rico, Dec	Pfizer and Moderna		ORF1ab gene	3 doses vs 2	-	3 doses: 19.25 (NR) 2 doses: 18.40 (NR)	0.85 (0.45 to 1.26)
Accorsi (Accorsi	2021 – Jan 2022, Omicron (95%) of new cases. Omicron made up 56% of positive cases in study and Delta made up 44%		Difference		2 doses vs unvaccinated	18.58 (NR)	18.40 (NR)	-0.18 (-0.49 to 0.13)
et al. 2022)			in median Ct values	N gene	3 doses vs 2	-	3 doses: 19.35 (NR) 2 doses: 18.52 (NR)	0.83 (0.51 to 1.20)
					2 doses vs unvaccinated	18.71 (NR)	18.52 (NR)	-0.19 (-0.49 to 0.09)
Poucou (Poucou	USA, July 2021 to January	Johnson & Johnson/Janssen	Viral load decay and days to negative PCR (tdays to PCR conversion)			Reference	-	0.51 (95% CI: 0.23, 1.09)
et al. 2022)	2022. In the study, 66% had Delta and 34% had Omicron	only one named but others also used	Duration of sl culture conve	nedding of vial rsion)	ble virus (days to	Reference	0.82 (95% CI: 0.39, 1.71)	p = 0.60
Fall (Fall et al. 2022)	USA, 22 November to 31 December 2021, Omicron	Pfizer/BioNTech, Moderna, Johnson & Johnson/Janssen	Range of Ct v	Range of Ct values from all available C		11 to 33⁵	11 to 34 ⁵	NR
Kislaya (Kislaya et al. 2022a)	Portugal, 6 December to 26 December 2021, initially Delta, but then Omicron (50.8%)	Pfizer/BioNTech, Moderna, AsgtraZeneca Johnson & Johnson/Janssen	Mean (standard deviation) Ct values			18.6 (4.8)	18.4 (4.5)	Confounder-adjusted mean difference between Omicron and Delta for unvaccinated: - 0.002(-0.6 to 0.6)

						Effect estimat	te
Study	Country, time, dominant variant	Vaccine	Outcomes		Unvaccinated (SD or IQR)	Vaccinated (SD or IQR)	Difference* (95% CI) or p value
				Completion < 113 days	-	18.5 (4.5)	Confounder-adjusted mean difference between Omicron and Delta: -0.7(-1.13 to - 0.28)
			Mean (standard deviation) Ct values for time since fully vaccinated	Completion 113-168 days	-	18.4 (4.5)	Confounder-adjusted mean difference between Omicron and Delta: 0.13(-0.14 to 0.39)
				Completion 169+ days	-	18.3 (4.6)	Confounder-adjusted mean difference between Omicron and Delta: 0.32(-0.08 to 0.73)
	Denmark, Dec 2021 to	Pfizer/BioNTech, Moderna, AsgtraZeneca Johnson & Johnson/Janssen	BA 1	Median Ct value	27.02	27.33	NR
Lyngse (Lyngse			67.1	Mean Ct value	27.20	27.50	NR
et al. 2022a)	January 2022, Omicron (BA.2:		BA.2	Median Ct value	25.42	26.97	NR
	45%)			Mean Ct value	26.07	26.88	NR
				2 doses < 3 months before PCR test	Reference	0.23 (0.00, 0.46)	p = 0.048
Qassim (Qassim	Quatar, Dec 2021 – Feb 2022,	Pfizor Modorno	Ctivalue	2 doses 3 to < 6 months before PCR test	Reference	-0.05 (-0.15, 0.06)	p = 0.389
et al. 2022)	BA.2 (NR)	Flizer, Moderna	Ct value	2 doses 6 to < 9 months before PCR test	Reference	-0.48 (-0.56, - 0.40)	p < .001
				2 doses ≥ 9 months before PCR test	Reference	-0.43 (-0.53, - 0.33)	p < .001
Partially vaccinate	ed, Omicron variant						
Kislaya (Kislaya et al. 2022a)	Portugal, 6 December to 26 December 2021, initially Delta, but then Omicron (50.8%)	Pfizer/BioNTech, Moderna, AsgtraZeneca Johnson & Johnson/Janssen	Mean (standard deviation) Ct values		18.6 (4.8)	18.5 (4.6)	Confounder-adjusted mean difference between Omicron

							Effect estimate		
Study	Country, time, dominant variant	Vaccine	Outcomes	Outcomes			Vaccinated (SD or IQR)	Difference* (95% CI) or p value	
								and Delta for unvaccinated: -0.002 (-0.6 to 0.6)	
Qassim (Qassim et al. 2022)	Quatar, Dec 2021 – Feb 2022, BA.2 (NR)	Pfizer, Moderna	Ct value (one vaccine dose)			Reference	-0.34 [-0.67, - 0.00]	p =0.050	
Booster vaccinate	ed, Delta variant	1			-	1			
				ORF1ab gene	3 doses vs 2	-	3 doses: 18.70 (NR) 2 doses: 17.28 (NR)	1.43 (0.92 to 2.07)	
	USA and Puerto Rico, Dec 2021 – Jan 2022, Omicron (95%) of new cases. Omicron made up 56% of positive cases in study and Delta made up 44%	Pfizer and Moderna			3 doses vs unvaccinated	17.84 (NR)	18.70 (NR)	0.87 (0.28 to 1.51)	
Accorsi (Accorsi et al. 2022)			Difference in median Ct	e in t N gene	3 doses vs 2	-	3 doses: 19.07 (NR) 2 doses: 17.52 (NR)	1.56 (0.95 to 2.07)	
			values		3 doses vs unvaccinated	18.28 (NR)	19.07 (NR)	0.80 (0.19 to 1.33)	
				S gene	3 doses vs 2	-	3 doses: 23.62 (NR) 2 doses: 20.24 (NR)	3.38 (2.74 to 3.98)	
					3 doses vs unvaccinated	19.58 (NR)	23.62 (NR)	4.05 (3.46 to 4.61)	
Levine- Tiefenbrun (Levine- Tiefenbrun et al. 2021a)	Israel, Jun-Sep 2021, Delta (93%)	Pfizer	Mean Ct value	e		27.7 (5.0)	29.1 (4.7)	2.43 (1.97 to 2.89)	
Levine- Tiefenbrun			Mean 31	30 days after bo -60 days after b	oster dose		29.4 (4.7)	2.7 (2.3 to 3.0) 1.3 (0.7 to 1.9)	
(Levine- Tiefenbrun et al. 2022)	Israel, Jun-Nov 2021, Delta (>93%)	Pfizer	Ct values 61	31-60 days after booster dose 61-120 days after booster dose		26.8 (5.0)	28.9 (4.5)	0.8 (-0.1 to 1.8)	

						Effect estimate			
Study	Country, time, dominant variant	Vaccine	Outcomes	Outcomes			Vaccinated (SD or IQR)	Difference* (95% CI) or p value	
Fall (Fall et al. 2022)	USA, 22 November to 31 December 2021, Omicron	Pfizer/BioNTech, Moderna, Johnson & Johnson/Janssen	Range of Ct values of samples collected ≤ 5 days from onset of symptoms			Range: 8 to 34 ⁵	Range: 8 to 33 ⁵	NR	
Kislaya (Kislaya et al. 2022a)	Portugal, 6 December to 26 December 2021, initially Delta, but then Omicron (50.8%)	Pfizer/BioNTech, Moderna, AsgtraZeneca Johnson & Johnson/Janssen	Range of Ct values in people aged 50 years or more			9 to 28 ⁵	9 to 30 ⁵	NR	
Fully vaccinated,	Delta variant		1						
			Median Ct value (UeS)			22.7 (19.1 to 27.3)	22.2 (18.9 to 26.9)	p=0.54	
Acharya	US, Jun-Aug 2021, Delta (>95%)	NR	Median Ct (UeS, symptomatic)			21.9 (18.9 to 26.1)	21.2 (18.9 to 25.8)	p=0.62	
(Acharya et al. 2021)			Median Ct (UeS	S, asymptomatic)		23.6 (19.8 to 28.7)	24.0 (20.3 to 29.1)	p=0.89	
			Median Ct (HYT	Median Ct (HYT, asymptomatic)			26.1 (22.7 to 28.8)	p=0.80	
				ORF1ab gene	3 doses vs 2	-	3 doses: 18.70 (NR) 2 doses: 17.28 (NR)	1.43 (0.92 to 2.07)	
					2 doses vs unvaccinated	17.84 (NR)	17.28 (NR)	-0.56 (-0.95 to -0.30)	
Accorsi (Accorsi et al. 2022)	USA and Puerto Rico, Dec 2021 – Jan 2022, Omicron (95%) of new cases. Omicron made up 56% of positive	Pfizer and Moderna	Difference in median Ct	N gene	3 doses vs 2	-	3 doses: 19.07 (NR) 2 doses: 17.52 (NR)	1.56 (0.95 to 2.07)	
	cases in study and Delta made up 44%		values		2 doses vs unvaccinated	18.28 (NR)	17.52 (NR)	-0.76 (-1.08 to -0.42)	
r				S gene	3 doses vs 2	-	3 doses: 23.62 (NR) 2 doses: 20.24 (NR)	3.38 (2.74 to 3.98)	
					2 doses vs unvaccinated	19.58 (NR)	20.24 (NR)	0.67 (0.29 to 1.04)	

						Effect estimat	е
Study	Country, time, dominant variant	Vaccine	Outcomes	Outcomes		Vaccinated (SD or IQR)	Difference* (95% Cl) or p value
		Sinovac		1 dose		22.5 (21 to 28)	p = 0.44
Barbosa (Barbosa	Brazil Jan-Oct 2021 NR	Sillovac	Median Ct	2 doses	NR	19 (17 to 24)	p > 0.99
et al. 2022)		AstraZeneca	(symptomatic)	1 dose		23 (18 to 26)	p > 0.99
		/ lotrazoneea		2 doses		22 (16 to 30)	p = 0.66
Blanguart	France, Jun-Jul 2021, Delta		Difference in Ct value (symptomatic)		-	-	-0.25 (-0.96 to 0.46)
(Blanguart et al.	(91%)	NR	Difference in Ct	value (asymptomatic)	-	-	1.68 (1.03 to 2.33)
2021)	France, Jun-Jul 2021, Delta		Difference in Ct	values (symptomatic)	-	-	-0.14 (-0.99 to 0.72)
2	(100%)		Difference in Ct	values (asymptomatic)	-	-	1.42 (0.61 to 2.24)
Chia (Chia et al.	Singapore, Apr-Jun 2021,	Dfizor & Modorno	Median Ct value	e (first positive test)	18.8 (14.9 to 22.7)	19.2 (15.2 to 22.2)	p=0.929
2021)	Delta (100%)		Median Ct value	Median Ct value (symptom onset)		19.2 (16.6 to 21.5)	p=0.279
Christensen	LIC Mar Aug 2024 Dalta	Diner Mederee	Median Ct value	(Abbott assay)	22.1	20.5	p=0.0018
(Christensen et al. 2022)	(77%)	Janssen	Median Ct value	(Hologic Panther assay)	23.5	22.2	p=0.0348
Elliott (Elliott et al. 2021)	UK, Jun-Jul 2021, Delta (100%)	NR	Median Ct value	3	23.1 (20.3 to 25.8)	27.6 (25.5 to 29.7)	p=0.01
		AstraZeneca	Median Ct value (symptomatic)		17.1	17.3	NR
Eyre (Eyre et al.	UK, Jan-Jul 2021, Delta	Pfizer			17.1	18.2	NR
2022)	(100%)	AstraZeneca	Proportion of rec	duction in transmission mediated	-	-	23% (17% to 33%)
		Pfizer	via index case C	t values at diagnosis	-	-	7% (5% to 10%)
Fall (Fall et al. 2022)	USA, 22 November to 31 December 2021, Omicron	Pfizer/BioNTech, Moderna, Johnson &	Range of Ct valu	ues from all available Ct samples	8 to 34 ⁵	8 to 33 ⁵	NR
		Johnson/Janssen	Madian Otwalus		40.0	10.0	
Griffin (Griffin et	US, May-Jul 2021, Delta	Janssen, Moderna,	Median Ct value	(URF1ab gene)	18.8	19.0	m. 0.05
al. 2021)	(>90%)	Pfizer	Median Ct value		19.3	19.5	p>0.05
			Median Ct value	(SC2N gene)	19.3	19.4	
Hagan (Hagan et al. 2021)	US, Jul-Aug 2021, Delta (100%)	Janssen, Moderna, Pfizer	positive RT-PCF	R (days)	11 (3 to 15)	9 (8 to 10)	p=0.37
	(10070)	1 11201	Proportion of CF	PE positive samples	42%	38%	NR
Hirotsu (Hirotsu et al. 2021)	Japan, Feb-Sep 2021, Delta (100%)	Moderna, Pfizer	Mean viral load	(log10 copies/ml)	6.0 (1.6)	6.5 (0.8)	NR
Hsu (Hsu et al. 2021)	Germany, Dec 2020-Aug 2021, Delta (100%)	Pfizer, Janssen, AstraZeneca, Moderna, Sputnik, Sinopharm	Mean Ct values		24.1 (6.4)	25.0 (6.7)	p<0.001

							Effect estimat	e
Study	Country, time, dominant variant	Vaccine	Outcomes		Unvaccinated (SD or IQR)	Vaccinated (SD or IQR)	Difference* (95% CI) or p value	
Kale (Kale et al. 2021)	India, Jan-May 2021, Delta (70%), Kappa (24%)	AstraZeneca	Median Ct values (unvaccinated = partially vaccinated)		21.1 (12.0 to 29.5)	23.2 (0.03 to 33.1)	p=0.82	
			Da		Day 0	24.5 (23.6 to 26.7)	25.5 (25.3 to 25.8)	NR
Kang (Kang et al.	China, May-Jun 2021, Delta	NR	Predicted median after symptom on:	Predicted median Ct value, days after symptom onset		27.9 (27.3 to 30.5)	29.7 (29.3 to 30.3)	NR
2022)	(10078)				Day 16	34.6 (34.0 to 36.6)	36.1 (35.9 to 36.5)	NR
			Difference in Ct value			-	-	0.97 (0.19 to 1.76)
Kerwin (Kerwin et al. 2021)	US, Feb-Jul 2021, Delta (74%)	NR	Median Ct value			21 (17 to 25)	22 (17 to 26)	p=0.83
Kislaya (Kislaya et al. 2022b)	Portugal, May-Jul 2021, Delta (100%)	Pfizer, Moderna	Mean Ct value	Mean Ct value			17.7 (5.7)	2.24 (0.85 to 3.64)
		Dfizor/DioNTooh	Mean (standard d	eviation) Ct valu	es	18.5 (5.0)	18.1 (4.8)	Confounder-adjusted mean difference between Omicron and Delta for unvaccinated: -0.002 (-0.6 to 0.6)
Kislaya (Kislaya et E al. 2022a) E (;	Portugal, 6 December to 26 December 2021, initially Delta, but then Omicron (50.8%)	Pfizer/BioNTech, Moderna, AsgtraZeneca Johnson & Johnson/Janssen	Mean (standard deviation) Ct	Completion <	113 days	-	18.9 (4.7)	Confounder-adjusted mean difference between Omicron and Delta: -0.7 (-1.13 to - 0.28)
			since fully vaccinated	Completion 113-168 days		-	18.0 (4.8)	Confounder-adjusted mean difference between Omicron and Delta: 0.13 (- 0.14 to 0.39)

					Effect estimate			
Study	Country, time, dominant variant	Vaccine	Outcomes		Unvaccinated (SD or IQR)	Vaccinated (SD or IQR)	Difference* (95% Cl) or p value	
				Completion 169+ days	-	17.8 (4.9)	Confounder-adjusted mean difference between Omicron and Delta: 0.32 (- 0.08 to 0.73)	
		Pfizer/BioNTech	Vaccine breakthro	ugh infection: Mean peak Ct	20.7 (19.8, 20.2)	20.5 (19.0, 21.0)	NR	
Kissler (Kissler et	USA November 28 2020 to	Johnson & Johnson/Janssen	Vaccine breakthro proliferation time (ugh infection: Mean days)	3.5 (3.0, 4.0)	3.2 (2.5, 4.0)	NR	
al. 2021)	August 11 2021	Moderna	Vaccine breakthro clearance time (da	ugh infection: Mean viral ays)	7.5 (6.8, 8.2)	5.5 (4.6, 6.5)	NR	
		NR vaccine	Vaccine breakthro duration (days)	ugh infection: Acute infection	11.0 (10.3, 11.8)	8.7 (7.6, 9.9)	NR	
Levine-Tiefenbrun (Levine- Tiefenbrun et al. 2021a)	Israel, Jun-Sep 2021, Delta (93%)	Pfizer	Mean Ct 7-30 c value 31-60 61-12 121-1 >180 Mean Ct value (ur the second dose	days after 2^{nd} dose days after 2^{nd} dose 0 days after 2^{nd} dose 80 days after 2^{nd} dose days after 2^{nd} dose days after 2^{nd} dose days after 2^{nd} dose days after 2^{nd} dose	27.7 (5.0)	26.9 (5.0) 31.2 (4.5) 29.3 (5.1) 27.2 (4.8) 27.0 (5.0) 26.7 (5.0)	0.22 (0.02 to 0.42) 4.56 (2.19 to 6.94) 2.63 (0.67 to 4.59) 0.58 (0.05 to 1.12) 0.29 (0.08 to 0.51) 0.06 (-0.16 to 0.29) -3.1 (-4.6 to -1.6)	
			the second dose)			00.0 (1.5)		
Levine-Terenbrun (Levine- Tiefenbrun et al. 2022)	Israel, Jun-Nov 2021, Delta (>93%)	Pfizer	Mean Ct 31-60 values 121-1 >180	Days after 2nd dose 0 days after 2nd dose 10 days after 2nd dose 80 days after 2nd dose days after 2nd dose	26.8 (5.0)	30.8 (4.5) 28.4 (5.0) 27.2 (4.8) 26.9 (5.0) 26.8 (5.0)	NR NR NR NR NR	
Li (Li et al. 2021)	China, May-Jun 2021, Delta	Sinovac,	Proportion of Ct va or fully vaccinated	alue <24 (<i>vaccinated</i> = partially)	49.6%	44.7%	n-0.22	
	(100%)	Sinopharm	Proportion of Ct va partially or fully va	alue 24-40 (<i>vaccinated</i> = ccinated)	36.5%	52.6%	p=0.23	
Luo (Luo et al.		Janssen Moderna	Mean Ct value		21.1	20.2	NR	
2021a, Luo et al.	US, Jan-Jul 2021, Delta	Janssen, Moderna, M	Mean Ct ≤5 days a	after symptom onset	20.3	20.3	NR	
2021b) ²	(100%) Pt	1 11201	Mean Ct >5 days a	after symptom onset	24.6	21.1	NR	
			Proportion of CPE	positive samples	74.4%	76.6%	NR	

				Effect estimate			
Study	Country, time, dominant variant	Vaccine	Outcomes	Unvaccinated (SD or IQR)	Vaccinated (SD or IQR)	Difference* (95% CI) or p value	
Lyngse (Lyngse et al. 2022b)	Denmark, Jun-Nov 2021, Delta	AstraZeneca, Janssen, Moderna, Pfizer	Mean Ct values	NR	NR	1.6	
Magalis (Magalis et al. 2021)	US, Oct 2020-Aug 2021, Delta (100%)	Janssen, Moderna, Pfizer	Mean viral load (log10 copies/ml)	7.36 (3.29 to 10.8)	4.66 (1.2 to 10.6)	p<0.00001	
Migueres (Migueres et al. 2022)	France, July to September 2021, Delta (NR)	Pfizer, Moderna, AstraZeneca. Unknown, Janssen	Mean viral load (log ₁₀ copies/ml) (IQR)	7.1 (5.7 to 7.9)	6.6 (5.4 to 7.5)	p < 0.0001	
Pena-Hernandez (Peña-Hernández et al. 2022)	US, Jul-Aug 2021, Delta	Moderna, Pfizer	Proportion of CPE positive samples	40%	21%	RR=0.49 (0.27 to 0.91)	
Pouwels (Pouwels	UK, May-Jun 2021, Delta (>61%)	Pfizer or	Median Ct value (seronegative)	21.5 (16.4 to 31.7)	32.3 (26.0 to 34.0)	NR	
et al. 2021)	UK, Jun-Aug 2021, Delta (>92%)	AstraZeneca		25.7 (19.1 to 30.8)	25.3 (19.1 to 31.3)	p=0.35	
			Ct value (E gene)	13.8 to 26.3	16.3 to 26.1	NR	
Puhach (Puhach	Switzerland, Apr 2020-Dec 2021, Delta	Pfizer, Moderna, CoviVac, other	Proportion of CPE positive samples	91.7%	83.8%	NR	
et al. 2022)			CPE positive samples at 5 days after symptom onset	84.6%	53.8%	NR	
Piemersma		mPNA or	Mean Ct value (N1)	23.3 (5.6)	22.8 (5.9)	p=0.23	
(Riemersma et al	US, Jun-Jul 2021, Delta (69%	adenovirus	Mean Ct value (N1, symptomatic)	22.9 (5.5)	22.6 (5.8)	p=0.74	
2021)	to 95%)	vaccines	Mean Ct value (N1, asymptomatic)	27.0 (5.6)	26.1 (7.1)	p=0.05	
			Proportion of CPE positive samples	88.2%	94.9%	NR	
			Median Ct value (day 1 of symptom onset or first positive test)	28.5 (24.8 to 31.8)	26.4 (23.5 to 28.4)	p>0.0026	
			Median Ct value (day 10 after symptom onset or positive test)	34.5 (29.4 to 35.2)	32.9 (30.5 to 34.6)	p>0.0026	
(Salvatore et al.	US, Jul-Aug 2021, Delta	Janssen, Moderna, Pfizer	Proportion of CPE positive samples	12%	8%	p=0.16	
2021)			Median duration of RT-PCR positivity	12 days	13 days	NR	
			Median duration of viral culture	5 days	5 days	p=0.29	
Servellita (Servellita et al. 2022)	US, Feb-Jun 2021, Delta (100%)	Moderna, Pfizer, Janssen	Mean Ct value (N gene)	19.5	21.5	p=0.09	

Siddle (Siddle et	US, Jul-Aug 2021, Delta	Janssen, Moderna,	Mean Ct values (asymptomatic)	24.1 (2.25)	24.0 (6.0)	NR
al. 2022)	(99%)	Pfizer	Mean Ct values (symptomatic)	24.3 (6.7)	24.4 (6.1)	NR

	Country time dominant					Effect estimate			
Study	variant	Vaccine	Outcome	Outcome		Unvaccinated (SD or IQR)	Vaccinated (SD or IQR)	Difference* (95% CI) or p value	
Singanayagam			Median viral load growth rate per day (ORF1ab gene)4			4.16 (2.19 to 11.8)	4.43 (3.01 to 10.2)	NR	
(Singanayagam et al. 2021)	UK, Sep 2020-Sep 2021, Delta (100%)	AstraZeneca, Pfizer	Median viral load gene)4	d decline rate per	day (ORF1ab	1.81 (1.52 to 2.2)	2.18 (1.88 to 2.57)	NR	
			Median peak log gene)4	10 viral load per	ml (ORF1ab	8.09 (7.74 to 8.42)	8.19 (7.99 to 8.41)	NR	
		Covaxin (Bharat Biotech) and AstraZeenca	Proportion expelling virus (within 48 hours of COVID-19 diagnosis)	Proportion AstraZeneca expelling virus (within 48 hours of Covaxin COVID-19 diagnosis)		92%	93%	NR	
	India, July – Sept 2021, Delta (NR)		Proportion	AstraZeneca	AstraZeneca		62%		
			expelling virus (8 – 12 days since diagnosis)	Covaxin		58%	90%	NR	
Sriraman (Sriraman et al			Median Ct value (IQR) within 48 hours of diagnosis	AstraZeneca	Nasopharyng eal sample		21 (17 to 27)	p = 0.123	
2022)					Mask sample	Nasopharyngeal:	31 (27 to 34)	p = 0.213	
- /				Caucavia	Nasopharyng eal sample	Mask: 34 (29 to 36)	23 (22 to 26)	p = 0.123	
				Covaxin	Mask sample		31 (27 to 35)	p = 0.213	
			Median Ct	AstraZeneca	Nasopharyng eal sample	Necohomyanash	32 (28 to 36)	p = 0.237	
			value (IQR)		Mask sample	27 (25 to 35)	35 (34 to 37)	p = 0.398	
			within 8 – 12 days since	Covaria	Nasopharyng eal sample	Mask: 37 (31 to 39)	33 (29 to 36)	p = 0.237	
			diagnosis		Mask sample		34 (32 to 37)	p = 0.398	
Yi (Yi et al. 2022)	South Korea, Aug 2021, Delta	Moderna, Pfizer	Mean Ct values	(asymptomatic)		17.2	Nasopharynge al sample	NR	
· · · · · ·	(100%)		Mean Ct values	(symptomatic)		15.1	20	NR	

	Ocument time dominant				Effect estimate			
Study	variant	Vaccine	Outcome			Unvaccinated (SD or IQR)	Vaccinated (SD or IQR)	Difference* (95% CI) or p value
Partially vaccinat	ed, Delta variant							
Elliott (Elliott et al. 2021)	UK, Jun-Jul 2021, Delta (100%)	NR	Median Ct value	Median Ct value		23.1 (20.3 to 25.8)	27.4 (24.8 to 30.0)	p=0.04
Eyre (Eyre et al. 2022)	UK, Jan-Jul 2021, Delta (100%)	Pfizer AstraZeneca	Proportion of reduction in transmission mediated via index case Ct values at diagnosis			-	-	12% (7% to 19%) 14% (11% to 17%)
Griffin (Griffin et al. 2021)	US, May-Jul 2021, Delta (>90%)	Janssen, Moderna, Pfizer	Median Ct value (<i>ORF1ab</i> gene) Median Ct value (<i>N</i> gene) Median Ct value (<i>SC2N</i> gene)			18.8 19.3 19.3	17.8 18.6 20.2	p>0.05
Hirotsu (Hirotsu et al. 2021)	Japan, Feb-Sep 2021, Delta (100%)	Moderna, Pfizer	Mean viral load (log10 copies/ml)			6.0 (1.6)	5.5 (2.2)	NR
Kislaya (Kislaya et al. 2022b)	Portugal, May-Jul 2021, Delta (100%)	Pfizer, Moderna	Mean Ct value			16.5 (4.9)	16.1 (5.0)	-0.15 (-0.99 to 0.96)
Kislaya (Kislaya et al. 2022a)	Portugal, 6 December to 26 December 2021, initially Delta, but then Omicron (50.8%)	Pfizer/BioNTech, Moderna, AsgtraZeneca Johnson & Johnson/Janssen	Mean (standard deviation) Ct values			18.5 (5.0)	19.5 (5.7)	Confounder-adjusted mean difference between Omicron and Delta for unvaccinated: -0.002(-0.6 to 0.6)
Migueres (Migueres et al. 2022)	France, July to September 2021, Delta (NR)	Pfizer, Moderna, AstraZeneca. Unknown, Janssen	Mean viral load (log ₁₀ copies/ml) (IQR)			7.1 (5.7 to 7.9)	7 (5.6 to 7.8)	NR
Pouwels (Pouwels et al. 2021)	UK, May-Jun 2021, Delta (>61%) UK, Jun-Aug 2021, Delta (>92%)	Pfizer, AstraZeneca	Median Ct value (s	seronegative)		21.5 (16.4 to 31.7) 25.7 (19.1 to 30.8)	30.1 (26.0 to 34.0) 24.7 (18.8 to 31.3)	NR NR
			Proportion expellin (within 48 hours of diagnosis)	ng virus f COVID-19	AstraZeneca Covaxin	92%	96% NR	NR NR
			Proportion expellin	ng virus (8 – anosis)	AstraZeneca Covaxin	58%	52% NR	NR NR
Sriraman (Sriraman et al. 2022)	India, July – Sept 2021, Delta (NR)	Covaxin (Bharat Biotech) and AstraZeenca	Median Ct value	AstraZenec a	Nasopharyng eal sample	Nasopharyngeal:	26 (22 to 28)	p = 0.123
			(IQR) within 48		Mask sample	27 (21 to 33)	33 (30 to 36)	p = 0.213
			hours of diagnosis	Covaxin	Nasopharyng eal sample	Mask: 34 (29 to 36)	17	p = 0.123
					Mask sample		26	p = 0.213

	Country time dominant					Effect estimate			
Study	variant	Vaccine	Outcome			Unvaccinated (SD or IQR)	Vaccinated (SD or IQR)	Difference* (95% CI) or p value	
			Median Ct value	AstraZenec	Nasopharyng eal sample	Nasopharyngeal:	33 (31 to 37)	p = 0.237	
			(IQR) within 8 –	<u> </u>	Mask sample	27 (25 to 35)	35 (32 to 37)	p = 0.398	
			diagnosis	Covaxin	eal sample	39)	Not detected	p = 0.237	
Fully vaccinated	pre-Delta variant				Mask sample		37	p = 0.398	
Adamson (Adamson et al. 2021)	US, Dec 2020-Mar 2021, NR	Janssen, Moderna, Pfizer	Median Ct value			20.1 (16.9 to 25.1)	30.4 (20.8 to 34.1)	NR	
Abu-Raddad	Qatar. Feb 2020-Jul 2021.	Pfizer	Mean Ct value Mean Ct value (symptomatic) Mean Ct value (asymptomatic)		24.0 (6.5) 22.5 (6.0) 25.5 (6.6)	25.0 (6.6) 22.7 (6.0) 26.8 (6.5)	1.0 (0.7 to 1.2) 0.2 (-0.2 to 0.6) 1.3 (0.9 to 1.8)		
(Abu-Raddad et al. 2022)	Wild-type, Alpha, Beta	Moderna	Mean Ct value Mean Ct value (symptomatic) Mean Ct value (asymptomatic)			26.8 (7.1) 21.7 (5.5) 28.0 (6.7)	30.3 (5.9) 26.6 (6.7) 31.2 (5.5)	3.5 (2.4 to 4.6) 4.9 (2.4 to 7.4) 3.2 (1.8 to 4.5)	
Bailly (Bailly et al. 2022)	France, Mar 2021, Beta	Pfizer	Mean Ct value			15	21	p<0.05	
Blanquart	France Jun-Jul 2021 non-		Difference in Ct va	alue (symptoma	atic)	-	-	-1.91 (-5.99 to 2.16)	
(Blanquart et al. 2021)	Delta (100%)	NR	Difference in Ct va	alue (asymptom	natic)	-	-	4.07 (1.84 to 6.31)	
Boschi (Boschi	France, Jan-July 2021, Alpha	AstraZeneca,	Mean Ct value			21.5 (4.5)	23.4 (5.4)	NR	
et al. 2021)	and Delta (percentages NR)	Janssen, Moderna, Pfizer	Proportion of CPE	positive sampl	es	80%	66%	p<0.0001	
Brunner-Ziegler (Brunner-Ziegler et al. 2022)	Austria, Jan-Jul 2021, Alpha (81%)	AstraZeneca, Pfizer	Mean Ct value			22.6 (7.1)	24.8 (6.4)	NR	
Costa (Costa et	Spain Feb-Jul 2021 Alpha	AstraZeneca	Mean viral load	All		8.1	7.8	p=0.31	
al. 2022)	(54%), Delta (46%)	Janssen, Pfizer	(log10	Asymptomatic		8.4	8.7	p=0.85	
	UK, May 2020-Jan 2021, Alpha (100%)	n 2021,		tables/ml) Symptomatic		15.2 (13.0 to 19.3)	19.3 (15.4 to 22.0)	p=0.026	
Emary (Emary et al. 2021)	UK, May 2020-Jan 2021,	AstraZeneca	Median Ot value			20.2 (15.5 to 29.6)	28.8 (20.5 to 33.5)	p<0.0001	
	(65%)		Median Ct value (symptomatic)		17.9 (15.0 to 25.1)	20.6 (15.4 to 24.5)	p=0.07	
Eyre (Eyre et al. 2022)	UK, Jan-Jul 2021, Alpha (100%)	AstraZeneca	Median Ct value (symptomatic)		18.4 (15.7 to 22.5)	23.9 (18.1 to 32.5)	NR	

	Country time dominant			Effect estimate			
Study	variant	Vaccine	Outcome	Unvaccinated (SD or IQR)	Vaccinated (SD or IQR)	Difference* (95% CI) or p value	
		Pfizer		18.4 (15.7 to 22.5)	27.4 (19.7 to 32.1)	NR	
		AstraZeneca	Proportion of reduction in transmission mediated	-	-	18% (9% to 64%)	
		Pfizer	via index case Ct values at diagnosis	-	-	16% (1% to 80%)	
Griffin (Griffin et al. 2021)	US, May-Jul 2021, Alpha (>50%)	Janssen, Moderna, Pfizer	Median Ct value (<i>ORF1ab</i> gene) Median Ct value (<i>N</i> gene)	22.8 24.0	27.2 30.6	p<0.05	
Hsu (Hsu et al. 2021)	Germany, Dec 2020-Aug 2021, Alpha (100%)	Pfizer, Janssen, AstraZeneca, Moderna, Sputnik, Sinopharm	Mean Ct values	26.9 (6.4)	33.1 (6.0)	p<0.001	
loannou (loannou et al. 2021)	Greece, Jan-Apr 2021, Alpha (98%)	Pfizer	Median Ct value	18.5 (13.5 to 24)	18.5 (16 to 26)	p=0.70	
looobaan			Mean Ct value	23.0 (7.4)	28.5 (7.4)	NR	
(Jacobson et al. 2022)	US, Dec-Apr 2021, L452R (39.5%)	Pfizer, Moderna	Mean Ct value (<i>unvaccinated</i> = unvaccinated/early post-vaccination, <i>vaccinated</i> = fully/partially vaccinated)	22.9	27.9	p<0.001	
Kislaya (Kislaya et al. 2022b)	Portugal, May-Jul 2021, Alpha (100%)	Pfizer, Moderna	Mean Ct value	18.4 (5.2)	21.8 (5.7)	4.49 (2.07 to 6.91)	
Kolobukhina (Kolobukhina et al. 2021)	Russia, Dec 2020-Apr 2021, NR	Sputnik V	Mean Ct value	31.5 (27.2 to 33.7)	34.8 (31.4 to 36.5)	p=0.026	
Lumley (Lumley	UK, Mar 2020-Feb 2021,	AstraZeneca,	Median Ct value (seronegative)	18.3 (14.0 to 25.5)	19.7 (15.0 to 27.5)	2.7 (-0.5 to 6.8)	
et al. 2021)	Alpha (56%)	Pfizer	Median Ct value (seropositive)	27.2 (18.8 to 32.2)	-	-	
Luo (Luo et al			Mean Ct values	21.7	22.7	NR	
2021a Luo et al	US, Jan-Jul 2021, Alpha	Pfizer, Moderna,	Mean Ct values ≤5 days after symptom onset	21.3	21.5	NR	
2021b) ²	(100%)	Janssen	Mean Ct values >5 days after symptom onset	24.6	24.2	NR	
			Proportion of CPE positive samples	37.9%	17.4%	p=0.02	
Magalis (Magalis et al. 2021)	US, Oct 2020-Aug 2021, non- Delta	Janssen, Moderna, Pfizer	Mean viral load (log10 copies/ml)	6.15 (3.56 to 10.9)	5.39 (1.41 to 8.36)	p<0.00001	
McEllistream (McEllistrem et	US, Dec 2020-Feb 2021, NR	Pfizer	Median Ct value	12.8 (12.4 to 14.9)	19.4 (18.9 to 25.5)	p=0.009	
al. 2021)			Mean log ₁₀ viral load	9.5 (9.3 to 9.8)	7.1 (5.4 to 8.8)	-2.4 (p=0.004)	
Mostafa (Mostafa et al.	US, Jan-May 2021, Alpha	Pfizer, Moderna	Median Ct value (N gene)	19.6 (16.3 to 22.8)	19.2 (16.6 to 22.0)	NR	
2021)	(0170), IOLA (13.370)	.,	Proportion of CPE positive samples	64.5%	18.5%	p<0.00001	

	Country time dominant				Effect estimate		
Study	variant	Vaccine	Outcome	Outcome		Vaccinated (SD or IQR)	Difference* (95% CI) or p value
Muhsen (Muhsen et al. 2021)	Israel, Jan-Apr 2021, Alpha (dominant)	Pfizer	Median Ct value (ORF1ab gene	e)	26.7 (28.7 to 33.5)	32.0 (22.9 to 31.0)	p=0.008
			Median time to viral clearance	(days)	7	4	3
Pajon (Pajon et al. 2021)				Day 1	20.26	27.27	7.01 (4.74 to 9.28)
	US, Jul 2020-Mar 2021, Wild-	Moderna	Estimated Ct values	Day 3	31.80	37.63	5.84 (3.03 to 8.64)
	type (B.1/B.1.2) (93%)		(symptomatic), days after	Day 5	34.07	39.87	5.80 (1.73 to 8.37)
			symptoms	Day 7	35.23	39.37	4.13 (1.73 to 6.54)
				Day 28	40.73	41.03	0.30 (-0.33 to 0.90)
Pouwels (Pouwels of al	UK, Dec 2020-May 2021,	Pfizer,	Median Ct value (seronegative) p value for trend (increasing Ct value with time from first vaccination and number of doses)		28.7 (20.4 to 32.9)	33.3 (31.6 to 34.0)	p=0.02
2021)	Alpha (dominant)	AstraZeneca			-	-	p<0.0001
Regev-Yochay	Israel Dec 2020 Mar 2021		Mean Ct value		22.2 (1.0)	27.3 (1.2)	5.09 (2.8 to 7.4)
(Regev-Yochay et al. 2021)	NR	Pfizer	Median Ct value		23.3	25.8	p<0.001
			Mean Ct value (N gene)		23.1	23.1	p=0.99
	US, Feb-Jun 2021, All		Mean Ct value (N gene, sympto	omatic)	21.9	21.2	p=0.64
			Mean Ct value (N gene, asymptomatic)		24.6	30.1	p=0.023
	US, Feb-Jun 2021, Alpha (100%)				21.5	22.1	p=0.70
Servellita	US, Feb-Jun 2021, Beta (100%)	Moderna, Pfizer,			22.8	26.5	p=0.27
(Servellita et al. 2022)	US, Feb-Jun 2021, Gamma (100%)	Janssen			19.8	20.2	p=0.78
	US, Feb-Jun 2021, Epsilon (100%)		Mean Ct value (N gene)		21.0	24.3	p=0.15
	US, Feb-Jun 2021, lota (100%)				21.8	20.9	p=0.64
	US, Feb-Jun 2021, Other (100%)				22.3	23.8	p=0.45
Smith (Smith et al. 2022)	Worldwide, Mar 2020-Nov 2021, Non-Delta (100%)	NR	Mean viral load (log10 PFU/ml)		3.2	3.1	NR
Tende (Tende - t			Maan Otwalua	Arizona (Alinity instrument)	26.6 (8.3)	30.0 (6.1)	NR
al. 2021)	US, Dec 2020-Feb 2021, NR	Pfizer, Moderna	Mean Ct value (asymptomatic)	Arizona (m2000 instrument)	15.1 (7.7)	18.6 (9.3)	NR

	Country time dominant					Effect estimate			
Study	variant	Vaccine	Outcome	Outcome		Vaccinated (SD or IQR)	Difference* (95% CI) or p value		
Thompson			Mean log10 viral copies/µL (vaccinated = partial or full vaccination)		3.8 (1.7)	2.3 (1.7)	40.2% (16.3% to 57.3%)1		
(Thompson et al.	US, Dec 2020-Apr 2021, Wild-type (70% to 90%)	Pfizer (67%), Moderna (33%)	Mean days of viral RNA detecti partial or full vaccination)	on (vaccinated =	8.9 (10.2)	2.7 (3.0)	6.2 (4.0 to 8.4)		
2021)			Mean days spent in sick bed (v partial or full vaccination)	accinated =	3.8 (5.9)	1.5 (2.1)	2.3 (0.8 to 3.7)		
Williams (Williams et al. 2021)	UK, March to April 2021, Alpha	NR	Mean Ct value		25.55	25.42	NR		
Partially vaccinat	ed, pre-Delta variant								
Brunner-Ziegler (Brunner-Ziegler et al. 2022)	Austria, Jan-Jul 2021, Alpha (81%)	AstraZeneca, Pfizer	Mean Ct value		22.6 (7.1)	25.5 (7.4)	NR		
Eyre (Eyre et al. 2022)	UK, Jan-Jul 2021, Alpha (100%)	Pfizer AstraZeneca	Proportion of reduction in transmission mediated via index case Ct values at diagnosis		-	-	33% (23% to 53%) 39% (30% to 50%)		
Griffin (Griffin et al. 2021)	US, May-Jul 2021, Alpha (>50%)	Janssen, Moderna, Pfizer	Median Ct value (<i>ORF1ab</i>) Median Ct value (<i>N</i>)		22.8 24.0	36.6 36.0	p<0.05		
Jacobson (Jacobson et al. 2022)	US, Dec-Apr 2021, L452R (39.5%)	Pfizer, Moderna	Mean Ct value		23.0 (7.4)	27.7 (8.7)	NR		
Jones (Jones et al. 2021)	UK, Jan 2021, Alpha	Pfizer	Median Ct value		23.4 (13.5 to 33.0)	30.3 (25.5 to 35.1)	p>0.05		
Kislaya (Kislaya et al. 2022b)	Portugal, May-Jul 2021, Alpha (100%)	Pfizer, Moderna	Mean Ct value		18.4 (5.2)	20.0 (5.6)	1.87 (0.2 to 3.53)		
Levine-				1-11 days	-	-	-0.07 (-0.19 to 0.06)		
Liefenburn	Israel, Dec 2020-Feb 2021,	Dünar	Mean Ct value (<i>RdRp</i>), days	12-21 days	-	-	1.75 (1.60 to 1.91)		
Tiefenbrun et al. 2021b)	NR	Prizer	post-vaccination	22-37 days	-	-	2.15 (1.87 to 2.42)		
Pouwels (Pouwels et al. 2021)	UK, Dec 2020-May 2021, Alpha (dominant)	Pfizer, AstraZeneca	Median Ct value (seronegative)		28.7 (20.4 to 32.9)	31.6 (26.6 to 33.7)	NR		
Shrotri (Shrotri et al. 2021)	UK, Dec 2020-Mar 2021, Alpha	AstraZeneca (67%), Pfizer (33%)	Mean Ct value		26.6 (6.6)	31.3 (8.7)	p<0.0001		
Tande (Tande et al. 2021)	US, Dec 2020-Feb 2021, NR	Pfizer (94%), Moderna (5.9%)	Mean Ct value (asymptomatic	Arizona (Alinity instrument)	26.6 (8.3)	30.5 (6.1)	NR		

Country time dominan					Effect estimate			
Study	variant	Vaccine	Outcome		Unvaccinated (SD or IQR)	Vaccinated (SD or IQR)	Difference* (95% CI) or p value	
				Arizona (m2000 instrument)	15.1 (7.7)	11.1 (7.1)	NR	
				Rochester	30.4 (4.4)	30.9 (-)	NR	
<i>CI</i> = confidence interval, <i>CPE</i> = cytopathic effect (i.e. infectious virus), HYT = Healthy Yolo Together (testing centre), <i>RR</i> = relative risk, <i>UeS</i> = Unidos en Salud (testing centre) *When a difference is not reported, a p-value presented instead if reported; ¹ Relative difference; ² Updated from previous report (pre-print was published or updated); ³ As reported in paper; ⁴ 2.5% and 97.5% centiles reported ⁵ data extracted from figure The studies included people who had received COVID-19 booster vaccinations (three doses), those who were fully vaccinated (two doses), those who were partially vaccinated (one dose), and those who were unvaccinated (no vaccine doses).								
Studies with black text are from this updated search; studies with grey text are from a previous search								

9. References

Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. (2022). Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections. Nature Communications. 13(1): 532. doi: https://dx.doi.org/10.1038/s41467-022-28199-7

Academy of Nutrition and Dietetics. (2016). Evidence analysis manual: steps in the Academy evidence analysis process. Available at: https://www.andeal.org/evidence-analysis-manual [Accessed 24 May 2022].

Accorsi EK, Britton A, Fleming-Dutra KE, et al. (2022). Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants. JAMA. 327(7): 639-51. doi: https://dx.doi.org/10.1001/jama.2022.0470

Acharya CB, Schrom J, Mitchell AM, et al. (2021). No significant difference in viral load between vaccinated and unvaccinated, asymptomatic and symptomatic groups when infected with SARS-CoV-2 Delta variant. MedRxiv. [Pre-print]. doi: https://doi.org/10.1101/2021.09.28.21264262

Adamson PC, Pfeffer MA, Arboleda VA, et al. (2021). Lower Severe Acute Respiratory Syndrome Coronavirus 2 viral shedding following coronavirus disease 2019 vaccination among healthcare workers in Los Angeles, California. Open Forum Infectious Diseases. 8(11): ofab526. doi: https://doi.org/10.1093/ofid/ofab526

Allen H, Tessier E, Turner C, et al. (2022a). Comparative transmission of SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants and the impact of vaccination: national cohort study, England. MedRxiv. [Pre-print]: 2022.02.15.22271001. doi: https://doi.org/10.1101/2022.02.15.22271001

Allen H, Vusirikala A, Flannagan J, et al. (2022b). Household transmission of COVID-19 cases associated with SARS-CoV-2 Delta variant (B.1.617.2): national case-control study. Lancet Regional Health Europe. 12: 100252. doi: https://doi.org/10.1016/j.lanepe.2021.100252

Allen H, Vusirikala A, Flannagan J, et al. (2021). Increased household transmission of COVID-19 cases associated with SARS-CoV-2 variant of concern B.1.617.2: a national case control study. PHE Publishing. [Pre-print]. doi:

https://khub.net/documents/135939561/405676950/Increased+Household+Transmission+of+COVID-19+Cases+-+national+case+study.pdf/7f7764fb-ecb0-da31-77b3-b1a8ef7be9aa

Andrejko KL, Pry J, Myers JF, et al. (2021). Predictors of Severe Acute Respiratory Syndrome Coronavirus 2 infection following high-risk exposure. Clinical Infectious Diseases. [Article-in-press]: ciab1040. doi: https://doi.org/10.1093/cid/ciab1040

Bailly B, Guilpain L, Bouiller K, et al. (2022). BNT162b2 messenger RNA vaccination did not prevent an outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 variant 501Y.V2 in an elderly nursing home but reduced transmission and disease severity. Clinical Infectious Diseases. 74(3): 517-20. doi: https://doi.org/10.1093/cid/ciab446

Barbosa G, Chaves APC, de Souza Luna L, et al. (2022). SARS-CoV-2 breakthrough infection and viral load among healthcare workers after COVID-19 vaccines. Journal of Medical Virology. 94(6): 2350-1. doi: https://dx.doi.org/10.1002/jmv.27639

Blanquart F, Abad C, Ambroise J, et al. (2021). Characterisation of vaccine breakthrough infections of SARS-CoV-2 Delta and Alpha variants and within-host viral load dynamics in the community, France, June July 2021. Euro Surveillance. 26(37): 2100824. doi: https://doi.org/10.2807/1560to 7917.ES.2021.26.37.2100824

Bobdey S, Kaushik SK, Sahu R, et al. (2021). Effectiveness of ChAdOx1 nCOV-19 vaccine: experience of a tertiary care institute. Medical Journal Armed Forces India. 77(Supplement 2): S271-7. doi: https://doi.org/10.1016/j.mjafi.2021.06.006

Bordas A, Soriano-Arandes A, Subirana M, et al. (2022). Study protocol for monitoring SARS-CoV-2 infection and its determinants in Catalonia (Spain): an observational and participatory research approach in a Sentinel Network of Schools. BMJ Open. 12(1): e055649. doi: https://dx.doi.org/10.1136/bmjopen-2021-055649

Boschi C, Aherfi S, Houhamdi L, et al. (2021). Isolation of 4000 SARS-CoV-2 shows that contagiousness is associated with viral load, not vaccine or symptomatic status. Emerging Microbes & Infections. 10(1): 2276-8. doi: https://doi.org/10.1080/22221751.2021.2008776

Boucau J, Marino C, Regan J, et al. (2022). Duration of viable virus shedding in SARS-CoV-2 omicron variant infection. MedRxiv. [Pre-print]. doi: https://dx.doi.org/10.1101/2022.03.01.22271582

Braeye T, Cornelissen L, Catteau L, et al. (2021). Vaccine effectiveness against infection and onwards transmission of COVID-19: analysis of Belgian contact tracing data, January-June 2021. Vaccine. 39(39): 5456-60. doi: https://doi.org/10.1016/j.vaccine.2021.08.060

Brandal LT, MacDonald E, Veneti L, et al. (2021). Outbreak caused by the SARS-CoV-2 Omicron variant Norway, November to December 2021. Euro Surveillance. 26(50): 2101147. doi: in https://dx.doi.org/10.2807/1560-7917.ES.2021.26.50.2101147

Brunner-Ziegler S, Spath T, Kornek G, et al. (2022). Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNAbased 596-601. vaccines. Clinical Microbiology and Infection. 28(4): doi: https://dx.doi.org/10.1016/j.cmi.2021.11.023

Chia PY, Xiang Ong SW, Chiew CJ, et al. (2021). Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study. MedRxiv. [Pre-print]. doi: https://doi.org/10.1101/2021.07.28.21261295

Christensen PA, Olsen RJ, Long SW, et al. (2022). Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas. American Journal of Pathology. 192(2): 320-31. doi: https://dx.doi.org/10.1016/j.ajpath.2021.10.019

Clifford S, Waight P, Hackman J, et al. (2021). Effectiveness of BNT162b2 and ChAdOx1 against SARS-CoV-2 household transmission: a prospective cohort study in England. MedRxiv. [Pre-print]. doi: https://doi.org/10.1101/2021.11.24.21266401

Costa R, Olea B, Bracho MA, et al. (2022). RNA viral loads of SARS-CoV-2 Alpha and Delta variants in nasopharyngeal specimens at diagnosis stratified by age, clinical presentation and vaccination status. Journal of Infection. 84(4): 579-613. doi: https://dx.doi.org/10.1016/j.jinf.2021.12.018

de Gier B, Andeweg S, Backer J, et al. (2021a). Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), August-September 2021, the Netherlands. MedRxiv. [Pre-print]. doi: https://doi.org/10.1101/2021.10.14.21264959

de Gier B, Andeweg S, Joosten R, et al. (2021b). Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February https://dx.doi.org/10.2807/1560-May 2021. Euro Surveillance. 26(31): 2100640. doi: to 7917.ES.2021.26.31.2100640

Elliott P, Haw D, Wang H, et al. (2021). REACT-1 round 13 final report: exponential growth, high prevalence of SARS-CoV-2 and vaccine effectiveness associated with Delta variant in England during May to July 2021. Imperial College London. [Pre-print]. doi: http://hdl.handle.net/10044/1/90800

Emary KRW, Golubchik T, Aley PK, et al. (2021). Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 397(10282): 1351-62. doi: https://dx.doi.org/10.1016/S0140-6736(21)00628-0

Eyre DW, Taylor D, Purver M, et al. (2022). Effect of Covid-19 vaccination on transmission of Alpha and Delta variants. New England Journal of Medicine. 386(8): 744-56. doi: https://dx.doi.org/10.1056/NEJMoa2116597

Fall A, Eldesouki RE, Sachithanandham J, et al. (2022). A quick displacement of the SARS-CoV-2 variant Delta with Omicron: unprecedented spike in COVID-19 cases associated with fewer admissions and comparable upper respiratory viral loads. MedRxiv. [Pre-print]. doi: https://dx.doi.org/10.1101/2022.01.26.22269927

Gazit S, Mizrahi B, Kalkstein N, et al. (2021a). BNT162b2 mRNA vaccine effectiveness given confirmed exposure: analysis of household members of coronavirus disease 2019 patients. Clinical Infectious Diseases. [Article-in-press]: ciab973. doi: https://doi.org/10.1093/cid/ciab973

Gazit S, Mizrahi B, Kalkstein N, et al. (2021b). BNT162b2 mRNA vaccine effectiveness given confirmed exposure; analysis of household members of COVID-19 patients. MedRxiv. [Pre-print]. doi: https://doi.org/10.1101/2021.06.29.21259579

Griffin JB, Haddix M, Danza P, et al. (2021). SARS-CoV-2 infections and hospitalizations among persons aged >/=16 years, by vaccination status - Los Angeles County, California, May 1-July 25, 2021. Morbidity and Mortality Weekly Report. 70(34): 1170-6. doi: https://doi.org/10.15585/mmwr.mm7034e5

Hagan LM, McCormick DW, Lee C, et al. (2021). Outbreak of SARS-CoV-2 B.1.617.2 (Delta) variant infections among incarcerated persons in a federal prison - Texas, July-August 2021. Morbidity and Mortality Weekly Report. 70(38): 1349-54. doi: https://doi.org/10.15585/mmwr.mm7038e3

Harris RJ, Hall JA, Zaidi A, et al. (2021a). Effect of vaccination on household transmission of SARS-CoV-Medicine. 2 in England. New England Journal of 385(8): 759-60. doi: https://doi.org/10.1056/NEJMc2107717

Harris RJ, Hall JA, Zaidi A, et al. (2021b). Impact of vaccination on household transmission of SARS-COV-2 England. Publishing. [Pre-print]. in PHE doi: https://khub.net/documents/135939561/390853656/Impact+of+vaccination+on+household+transmission

+of+SARS-COV-2+in+England.pdf/35bf4bb1-6ade-d3eb-a39e-9c9b25a8122a?version=1.1&t=1619601878136&download=true

Hirotsu Y, Tsutsui T, Kakizaki Y, et al. (2021). Active immunization by COVID-19 mRNA vaccine results in rapid antibody response and virus reduction in breakthrough infection by Delta (B.1.617.2). Research Square. [Pre-print]. doi: https://doi.org/10.21203/rs.3.rs-957198/v1

Hsu L, Grüne B, Buess M, et al. (2021). COVID-19 breakthrough infections and transmission risk: realworld data analyses from Germany's largest public health department (Cologne). Vaccines (Basel). 9(11): 1267. doi: https://doi.org/10.3390/vaccines9111267

Ioannou P, Karakonstantis S, Astrinaki E, et al. (2021). Transmission of SARS-CoV-2 variant B.1.1.7 health Infectious among vaccinated care workers. Diseases. 53(11): 876-9. doi: https://doi.org/10.1080/23744235.2021.1945139

Jacobson KB, Pinsky BA, Montez Rath ME, et al. (2022). Post-vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections and incidence of the presumptive B.1.427/B.1.429 variant among healthcare personnel at a Northern California academic medical center. Clinical Infectious Diseases. 74(5): 821-8. doi: <u>https://doi.org/10.1093/cid/ciab554</u>

Jalali N, Brustad HK, Frigessi A, et al. (2022). Increased household transmission and immune escape of the SARS-CoV-2 Omicron variant compared to the Delta variant: evidence from Norwegian contact tracing and vaccination data. MedRxiv. [Pre-print] doi: https://doi.org/10.1101/2022.02.07.22270437

Jones NK, Rivett L, Seaman S, et al. (2021). Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection. eLife. 10: e68808. doi: https://doi.org/10.7554/eLife.68808

Kale P, Gupta E, Bihari C, et al. (2021). Vaccine breakthrough infections by SARS-CoV-2 variants after nCoV-19 vaccination in healthcare workers. Vaccines (Basel). 10(1): 54. ChAdOx1 doi: https://doi.org/10.3390/vaccines10010054

Kang M, Xin H, Yuan J, et al. (2022). Transmission dynamics and epidemiological characteristics of SARS-CoV-2 Delta variant infections in Guangdong, China, May to June 2021. Euro Surveillance. 27(10): 2100815. doi: https://dx.doi.org/10.2807/1560-7917.ES.2022.27.10.2100815

Kerwin H, Briggs R, Nair-Desai S, et al. (2021). An analysis of SARS-CoV-2 vaccine breakthrough infections and associated clinical outcomes. MedRxiv. [Pre-print]. doi: https://doi.org/10.1101/2021.09.09.21262448

Kislaya I, Peralta Santos A, Borges V, et al. (2022a). Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) MedRxiv. [Pre-print] doi: variants. https://doi.org/10.1101/2022.01.31.22270200

Kislaya I, Rodrigues EF, Borges V, et al. (2022b). Comparative effectiveness of coronavirus vaccine in preventing breakthrough infections among vaccinated persons infected with Delta and Alpha variants. Emerging Infectious Diseases. 28(2): 331-7. doi: https://dx.doi.org/10.3201/eid2802.211789

Kissler SM, Fauver JR, Mack C, et al. (2021). Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated persons. New England Journal of Medicine. 385(26): 2489-91. doi: https://dx.doi.org/10.1056/NEJMc2102507

Kolobukhina L, Burgasova O, Kruzhkova I, et al. (2021). Assessment of COVID-19 clinical course in patients vaccinated with Spitnik V, SARS-CoV-2 S protein RBD domain variation and serum virus neutralizing activity. Bulletin of RSMU. (5): 62-70. doi: https://doi.org/10.24075/brsmu.2021.046

Layan M, Gilboa M, Gonen T, et al. (2022). Impact of BNT162b2 vaccination and isolation on SARS-CoV-2 transmission in Israeli households: an observational study. American Journal of Epidemiology. [Articlein-press]: kwac042. doi: https://dx.doi.org/10.1093/aje/kwac042

Levine-Tiefenbrun M, Yelin I, Alapi H, et al. (2022). Waning of SARS-CoV-2 booster viral-load reduction effectiveness. Nature Communications. 13(1): 1237. doi: https://dx.doi.org/10.1038/s41467-022-28936-y

Levine-Tiefenbrun M, Yelin I, Alapi H, et al. (2021a). Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2. Nature Medicine. 27(12): 2108-10. doi: https://doi.org/10.1038/s41591-021-01575-4

Levine-Tiefenbrun M, Yelin I, Katz R, et al. (2021b). Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nature Medicine. 27(5): 790-2. doi: https://dx.doi.org/10.1038/s41591-021-01316-7

Li XN, Huang Y, Wang W, et al. (2021). Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study. Emerging Microbes & Infections. 10(1): 1751-9. doi: https://doi.org/10.1080/22221751.2021.1969291

Lumley S, Rodger G, Constantinides B, et al. (2021). An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status. MedRxiv. [Pre-print]. doi: https://doi.org/10.1101/2021.03.09.21253218

Luo CH, Morris CP, Sachithanandham J, et al. (2021a). Infection with the SARS-CoV-2 Delta variant is associated with higher infectious virus loads compared to the Alpha variant in both unvaccinated and vaccinated individuals. MedRxiv. [Pre-print]. doi: https://doi.org/10.1101/2021.08.15.21262077

Luo CH, Morris CP, Sachithanandham J, et al. (2021b). Infection with the SARS-CoV-2 Delta variant is associated with higher recovery of infectious virus compared to the Alpha variant in both unvaccinated and vaccinated individuals. Clinical Infectious Diseases. [Article-in-press]: ciab986. doi: https://doi.org/10.1093/cid/ciab986

Lyngse FP, Kirkeby CT, Denwood M, et al. (2022a). Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish Households. MedRxiv. [Pre-print]. doi: https://dx.doi.org/10.1101/2022.01.28.22270044

Lyngse FP, Mølbak K, Denwood M, et al. (2022b). Effect of vaccination on household transmission of SARS-CoV-2 Delta VOC. MedRxiv. [Pre-print]. doi: https://dx.doi.org/10.1101/2022.01.06.22268841

Lyngse FP, Mortensen LH, Denwood MJ, et al. (2021). SARS-CoV-2 Omicron VOC transmission in Danish households. MedRxiv. [Pre-print]. doi: https://dx.doi.org/10.1101/2021.12.27.21268278

Magalis BR, Rich S, Tagliamonte MS, et al. (2021). SARS-CoV-2 Delta vaccine breakthrough transmissibility in Alachua, Florida. MedRxiv. [Pre-print]. doi: https://doi.org/10.1101/2021.11.10.21266134

Martinez-Baz I, Trobajo-Sanmartin C, Miqueleiz A, et al. (2021). Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. Euro Surveillance. 26(39): 2100894. doi: https://doi.org/10.2807/1560-7917.ES.2021.26.39.2100894

McEllistrem MC, Clancy CJ, Buehrle DJ, et al. (2021). Single dose of a mRNA Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) vaccine is associated with lower nasopharyngeal viral load among nursing home residents with asymptomatic coronavirus disease 2019 (COVID-19). Clinical Infectious Diseases. 73(6): e1365-7. doi: https://dx.doi.org/10.1093/cid/ciab263

Meyer E, Sandfort M, Bender J, et al. (2021). Two doses of the mRNA BNT162b2 vaccine reduce severe outcomes, viral load and secondary attack rate: evidence from a SARS-CoV-2 Alpha outbreak in a nursing January-March 2021. home in Germany, MedRxiv. [Pre-print]. doi: https://doi.org/10.1101/2021.09.13.21262519

Migueres M, Dimeglio C, Trémeaux P, et al. (2022). Influence of the Delta variant and vaccination on the SARS-CoV-2 viral load. Viruses. 14(2): 323. doi: https://dx.doi.org/10.3390/v14020323

Mostafa HH, Luo CH, Morris CP, et al. (2021). SARS-CoV-2 infections in mRNA vaccinated individuals are biased for viruses encoding spike E484K and associated with reduced infectious virus loads that respiratory lgG MedRxiv. [Pre-print]. doi: correlate with antiviral levels. https://doi.org/10.1101/2021.07.05.21259105

Muhsen K, Maimon N, Mizrahi A, et al. (2021). Effectiveness of BNT162b2 mRNA coronavirus disease 2019 (COVID-19) vaccine against acquisition of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) among healthcare workers in long-term care facilities: a prospective cohort study. Clinical Infectious Diseases. [Article-in-press]: ciab918. doi: https://doi.org/10.1093/cid/ciab918

Ng OT, Koh V, Chiew CJ, et al. (2021). Impact of Delta variant and vaccination on SARS-CoV-2 secondary attack rate among household close contacts. Lancet Regional Health West Pacific. 17: 100299. doi: https://doi.org/10.1016/j.lanwpc.2021.100299

Page MJ, McKenzie JE, Bossuyt PM, et al. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 372: n71. doi: https://doi.org/10.1136/bmj.n71

Pajon R, Paila YD, Girard B, et al. (2021). Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 phase 3 COVE trial. MedRxiv. [Pre-print]. doi: https://doi.org/10.1101/2021.09.28.21264252

Peña-Hernández MA, Klein J, Malik AA, et al. (2022). Comparison of infectious SARS-CoV-2 from the vaccinated unvaccinated individuals. MedRxiv. nasopharynx of and [Pre-print]. doi: https://dx.doi.org/10.1101/2021.12.28.21268460

Pouwels KB, Pritchard E, Matthews PC, et al. (2021). Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nature Medicine. 27(12): 2127-35. doi: https://doi.org/10.1038/s41591-021-01548-7

Prunas O, Warren JL, Crawford FW, et al. (2022). Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 Science. to household contacts in Israel. 375(6585): 1151-4. doi: https://dx.doi.org/10.1126/science.abl4292

Puhach O, Adea K, Hulo N, et al. (2022). Infectious viral load in unvaccinated and vaccinated patients infected with SARS-CoV-2 WT. Delta and Omicron. MedRxiv. [Pre-print]. doi: https://dx.doi.org/10.1101/2022.01.10.22269010

Qassim SH, Chemaitelly H, Ayoub HH, et al. (2022). Effects of BA.1/BA.2 subvariant, vaccination, and prior infection on infectiousness of SARS-CoV-2 Omicron infections. MedRxiv. [Pre-print]. doi: https://doi.org/10.1101/2022.03.02.22271771

Regev-Yochay G, Amit S, Bergwerk M, et al. (2021). Decreased infectivity following BNT162b2 vaccination: a prospective cohort study in Israel Lancet Regional Health Europe. 7: 100150. doi: https://doi.org/10.1016/j.lanepe.2021.100150

Riemersma KK, Grogan BE, Kita-Yarbro A, et al. (2021). Shedding of infectious SARS-CoV-2 despite vaccination. MedRxiv. [Pre-print]. doi: https://doi.org/10.1101/2021.07.31.21261387

Salo J, Hägg M, Kortelainen M, et al. (2021). The indirect effect of mRNA-based COVID-19 vaccination unvaccinated household members. MedRxiv. [Pre-print]. doi: on https://doi.org/10.1101/2021.05.27.21257896

Salvatore PP, Lee CC, Sleweon S, et al. (2021). Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July-August 2021. MedRxiv. [Preprint]. doi: https://doi.org/10.1101/2021.11.12.21265796

Servellita V, Morris MK, Sotomayor-Gonzalez A, et al. (2022). Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California. Nature Microbiology. 7(2): 277-88. doi: https://dx.doi.org/10.1038/s41564-021-01041-4

Shah ASV, Gribben C, Bishop J, et al. (2021). Effect of vaccination on transmission of SARS-CoV-2. New England Journal of Medicine. 385(18): 1718-20. doi: https://doi.org/10.1056/NEJMc2106757

Shrotri M, Krutikov M, Palmer T, et al. (2021). Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. Lancet Infectious Diseases. 21(11): 1529-38. doi: https://dx.doi.org/10.1016/S1473-3099%2821%2900289-9

Siddle KJ, Krasilnikova LA, Moreno GK, et al. (2022). Transmission from vaccinated individuals in a large SARS-CoV-2 outbreak. Cell. 185(3): 485-92.e10. Delta variant doi: https://dx.doi.org/10.1016/j.cell.2021.12.027

Singanayagam A, Hakki S, Dunning J, et al. (2021). Community transmission and viral load kinetics of the SARS-CoV-2 Delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a longitudinal, cohort study. Lancet Infectious Diseases. 22(2): 183-95. doi: prospective, https://doi.org/10.1016/S1473-3099(21)00648-4

Smith DR, Singh C, Green J, et al. (2022). Genomic and virological characterization of SARS-CoV-2 variants in a subset of unvaccinated and vaccinated U.S. military personnel. Frontiers in Medicine. 8: 836658. doi: https://doi.org/10.3389/fmed.2021.836658

Sriraman K, Shaikh A, Vaswani S, et al. (2022). Impact of Delta and vaccination on SARS-CoV-2 transmission risk: lessons for emerging breakthrough infections. MedRxiv. [Pre-print]. doi: https://doi.org/10.1101/2022.03.02.22271385

Tande AJ, Pollock BD, Shah ND, et al. (2021). Impact of the coronavirus disease 2019 (COVID-19) vaccine on asymptomatic infection among patients undergoing preprocedural COVID-19 molecular screening Clinical Infectious Diseases. 74(1): 59-65. doi: https://doi.org/10.1093/cid/ciab229

Thompson MG, Burgess JL, Naleway AL, et al. (2021). Prevention and attenuation of COVID-19 with the BNT162b2 and mRNA-1273 vaccines. New England Journal of Medicine. 385(4): 320-9. doi: https://doi.org/10.1056/NEJMoa2107058

Tricco A, Langlois E, Straus S. (2017). Rapid reviews to strengthen health policy and systems: a practical World guide. Geneva: Health Organization. Available at: https://apps.who.int/iris/bitstream/handle/10665/258698/9789241512763-eng.pdf [Accessed 24 May 2022].

UKHSA. (2022). The effect of vaccination on transmission of COVID-19. A rapid evidence briefing. A rapid evidence briefing. Update 1: Search to 12 January 2022. COVID-19 Rapid Evidence Service. UK Health Security Agency. Available at: https://ukhsa.koha-ptfs.co.uk/cgi-bin/koha/opacdetail.pl?biblionumber=64682&query_desc=The%20effect%20of%20vaccination%20on%20transmission %20of%20COVID-19 [Accessed 24 May 2022].

West S, King V, Carey TS, et al. (2002). Systems to rate the strength of scientific evidence. Evidence report/technology assessment No. 47. Agency for Healthcare Research and Quality. Available at: https://www.ncbi.nlm.nih.gov/books/NBK33881/ [Accessed 24 May 2022].

Williams GH, Llewelyn A, Brandao R, et al. (2021). SARS-CoV-2 testing and sequencing for international arrivals reveals significant cross border transmission of high risk variants into the United Kingdom. eClinicalMedicine. 38: 101021. doi: https://dx.doi.org/10.1016/j.eclinm.2021.101021

Yi S, Kim JM, Choe YJ, et al. (2022). SARS-CoV-2 Delta variant breakthrough infection and onward secondary transmission in household. Journal of Korean Medical Science. 37(1): e12. doi: https://dx.doi.org/10.3346/jkms.2022.37.e12

10. Annex A: Methods

This is an update to a previously published review (UKHSA 2022), and employed a rapid review approach to address the review question:

Does vaccination against SARS-CoV-2 affect transmission of SARS-CoV-2 to others in the subgroup of people who contract COVID-19 post-vaccination?

We were also interested in the effects of vaccination on transmission according to vaccine type, individual vaccine brands, duration after vaccination, completion of the vaccination course, age and sex of index cases, SARS-CoV-2 variants in index cases, and background SARS-CoV-2 infection rate.

Our rapid review approach follows streamlined systematic methodologies (Tricco et al. 2017). In particular, 10% of the screening on title and abstract were screened in duplicate; full text screening, data extraction and risk of bias assessment were performed by one reviewer and checked by another. The review has been reported according to PRISMA guidelines (Page et al. 2021).

Protocol

A protocol was produced by the project team before the literature search began, specifying the research question and the inclusion and exclusion criteria. The review was registered prospectively on PROSPERO (CRD42021257125).

Review questions

- 1. What is the evidence on SARS-CoV-2 transmission from people who have had one or two doses of a COVID-19 vaccination?
- 2. How does risk of onward transmission vary with vaccine type, completion of the vaccination course, duration after vaccination, at different baseline community transmission levels and SARS-CoV-2 variant in the vaccinated person?

Sources searched

Ovid Medline, Ovid Embase, CENTRAL, medRxiv and SSRN pre-prints, WHO COVID-19 Research Database.

Search strategy

Searches were conducted for papers published between 12 January 2022 and 15 March 2022. The previous review included the same search strategy for papers published between 22 October 2021 and 12 January 2022. Studies included in the previous review are also included in this review.

Search terms covered key aspects of the review question. The search strategy for Ovid Medline is presented in Box A.1. Additionally, we checked reference lists of relevant systematic reviews and evidence summaries and consulted with topic experts. All that had been identified as pre-prints as of 12 January 2022 were last checked and updated (if necessary) on 6 April 2022.

Box A.1. Search strategy Ovid Medline

1.	vaccinat*.tw,kw.
2.	vaccine*.tw,kw.
3.	previously-vaccin*.tw,kw.
4.	post-vaccin*.tw,kw.
5.	early-vaccin*.tw,kw.
6.	late-vaccin*.tw,kw.
7.	moderna.tw,kw.
8.	mRNA-1273.tw,kw.
9.	pfizer.tw,kw.
10.	BNT162b2.tw,kw.
11.	JNJ-78436735.tw,kw.
12.	"Johnson & Johnson*".tw,kw.
13.	Astrazeneca.tw,kw.
14.	Oxford-Astrazeneca.tw,kw.
15.	AZD 1222.tw,kw.
16.	AZD1222.tw,kw.
17.	BNT 162b2.tw,kw.
18.	ChAdOx1.tw,kw.
19.	Novavax.tw,kw.
20.	NVX-CoV2373.tw,kw.
21.	Sputnik V.tw,kw.
22.	Ad26.tw,kw.
23.	"Ad26.COV2".tw,kw.
24.	Ad5.tw,kw.
25.	Janssen.tw,kw.
26.	Sinovac.tw,kw.
27.	sinopharm.tw,kw.
28.	COVAXIN.tW,KW.
29.	exp vaccination/
30.	
31. 20 or	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 19 or
20 01	21 01 22 01 23 01 24 01 25 01 20 01 27 01 26 01 29 01 30 (breaktbrough ar break through) the law
ు∠. ఎం	tropomico* tw kw
33. 24	transmit* tw kw
25	viral load* tw law
36	viral burden tw.kw
30.	((severity or severe) adi2 (disease or illness)) tw kw
38	Viral Load/
30.	exp Disease Transmission Infectious/
40	32 or 33 or 34 or 35 or 36 or 37 or 38 or 39
41	exp coronavirus/
42	exp Coronavirus Infections/
43	COVID-19/
.0.	

44. ((corona* or corono*) adj1 (virus* or viral* or virinae*)).ti,ab,kw.
45. (coronavirus* or coronovirus* or coronavirinae* or CoV or HCoV*).ti,ab,kw.
46. covid*.nm.
47. (2019-nCoV or 2019nCoV or nCoV2019 or nCoV-2019 or COVID-19 or COVID19 or CORVID-19 or CORVID-19 or CORVID19 or WN-CoV or WNCoV or HCoV-19 or HCoV19 or 2019 novel* or Ncov or n-cov or SARS-CoV-2 or SARSCoV-2 or SARSCoV2 or SARS-CoV2 or SARSCov19 or SARS-Cov19 or SARSCov-19 or SARS-Cov-19 or Ncovor or Ncorona* or Ncorono* or NcovWuhan* or NcovHubei* or NcovChina* or NcovChinese* or SARS2 or SARS-2 or SARScoronavirus2 or SARS-coronavirus2 or SARScoronavirus2 or SARScoronavirus2 or SARS-cov-19 or SARS-Cov-19 or SARS-Cov-19 or SARS-Cov-19 or SARS-2 o
CORONOVITUSZ). II, 2D, KW. 49. (reappiretent/* adi2 (aumptem* or diseases* or illness* or condition*) adi40. (Muban* or Hubai* or China* or
40. (respiratory adj2 (symptom of disease of limess of condition) adj10 (wuntan of Huber of China of Chinases or Huapan*)) ti ab kw
49 ((seafood market* or food market* or pneumonia*) adi10 (Wuhan* or Hubei* or China* or Chinese* or
Huanan*)).ti.ab.kw.
50. ((outbreak* or wildlife* or pandemic* or epidemic*) adj1 (Wuhan* or Hubei or China* or Chinese* or
Huanan*)).ti,ab,kw.
51. or/41-50
52. 31 and 40 and 51
53. COVID-19/tm [Transmission]
54. 31 and 53
55. COVID-19 Vaccines/
56. 40 and 55
57. COVID-19/vi [Virology]
58. 31 and 57
59. 52 or 54 or 56 or 58

Inclusion and exclusion criteria

Article eligibility criteria are summarised in Table A.1.

In the protocol, we stated we would include disease severity as an outcome. However, as more transmission evidence became available, the need to include disease severity as a secondary outcome became less necessary, and as with the previous review, we focussed this review on transmission and viral load only. We also stated in the protocol that we would exclude studies where the only index cases were children, as they were not eligible for vaccination when the protocol was written. As in the previous review, we have removed this exclusion criteria. We have also removed the need for contacts to be unvaccinated in transmission studies from the inclusion criteria.

	Table A	.1. Inc	lusion	and	exclusion	criteria
--	---------	---------	--------	-----	-----------	----------

	Included	Excluded
Population	People who developed laboratory-confirmed symptomatic or asymptomatic COVID-19 (index cases)	
Settings	All community settings, including households	Healthcare settings
Context	COVID-19 pandemic	Other diseases

	Included	Excluded
Intervention / exposure	Partial, full or booster vaccination against COVID-19; any COVID-19 specific vaccination	
Outcomes	 Direct outcomes Secondary transmission Transmission of laboratory-confirmed SARS-CoV-2 to contacts (secondary cases, assessed as transmission by genomic analysis or proximity, such as household members) Indirect outcomes Viral load Duration of infection (if presented with a direct outcome or viral load) 	
Language	English	
Date of publication	12 January 2022 to 15 March 2022	
Study design	 Randomised controlled trials Cohort study Case-control study The eligibility criteria for the update review were expanded slightly to include non-comparative studies reporting transmission rates for the Omicron (or different variants) in vaccinated populations.	 Systematic or narrative reviews Guidelines Opinion pieces Outbreak investigations, unless they include an analytical component
Publication type	Published and pre-print	

Screening

Title and abstract screening were completed by 2 reviewers: 10% of the eligible studies were screened in duplicate (disagreements were resolved by discussion) and the remainder were screened by 1 reviewer.

Full text screening was completed by one reviewer and checked by a second.

The PRISMA diagram showing the flow of citations is provided in Figure A.1.

Data extraction and risk of bias assessment

Data extraction was completed by 1 reviewer and checked by a second. Only results directly relevant to the review questions were extracted.

Studies were assessed using the quality criteria checklist (QCC) for primary research (Academy of Nutrition and Dietetics 2016). This risk of bias tool can be applied to most study designs (observational and interventional) and is therefore suitable for rapid reviews of mixed type of evidence. It is composed of 10 validity questions based on the criteria and domains identified by the Agency for Healthcare Research and Quality to assess the methodological quality of a study (that is, the extent to which a study has minimised selection, measurement and confounding biases) (West et al. 2002). In the QCC tool, 4 questions are considered critical (on selection bias, group comparability/confounding, interventions/exposure and outcome). A study will be rated as high quality if the answers to the 4 critical questions are 'yes' (and at least one additional 'yes'). The study will be rated as low quality if 2 or more of the critical questions are answered 'no' and/or if ≥50% of the remaining questions are answered 'no'. Otherwise, the study will be rated as medium quality. Judgments were made on case by case for questions answered as 'unclear'. To note that we report these ratings as 'quality' ratings for consistency with the name of the tool, although here quality needs to be understood as 'methodological quality' as part of a risk of bias assessment.

QCC ratings are reported in the data extraction tables, Supplementary Tables 1 and 2.

Variations across populations and subgroups, for example cultural variations or differences between ethnic, social or vulnerable groups were considered, where evidence was available.

Figure A.1. PRISMA diagram (for updated review)



medRxiv preprint doi: https://doi.org/10.1101/2022.12.09.22283255; this version posted December 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

11. About the Wales COVID-19 Evidence Centre

The WCEC integrates with worldwide efforts to synthesise and mobilise knowledge from research.

We operate with a core team as part of Health and Care Research Wales, are hosted in the Wales Centre for Primary and Emergency Care Research (PRIME), and are led by Professor Adrian Edwards of Cardiff University.

The core team of the centre works closely with collaborating partners in Health Technology Wales, Wales Centre for Evidence-Based Care, Specialist Unit for Review Evidence centre, SAIL Databank, Bangor Institute for Health & Medical Research/ Health and Care Economics Cymru, and the Public Health Wales Observatory.

Together we aim to provide around 50 reviews per year, answering the priority questions for policy and practice in Wales as we meet the demands of the pandemic and its impacts.

Director: Professor Adrian Edwards

Contact Email: WC19EC@cardiff.ac.uk

Website including report library: https://healthandcareresearchwales.org/about-researchcommunity/wales-covid-19-evidence-centre

Prepared by: Jessica Williams, Lauren Elston, Jenni Washington and Thomas Winfield from Health **Technology Wales**